{"title": "Harriet Kluger", "author": "Harriet Kluger", "url": "https://www.yalemedicine.org/specialists/harriet-kluger", "hostname": "yalemedicine.org", "description": "Dr. Kluger is a medical oncologist who sees patients with melanoma and renal cell carcinoma. Her research interests focus on developing new drug regimens and biomarkers predictive of response to therapies in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs an active research laboratory that studies tumor and immune cells from patients treated with novel therapies to determine mechanisms of resistance to therapy and mediators of toxicity from immune checkpoint inhibitors. The laboratory also conducts pre-clinical studies to improve treatment regimens for patients with melanoma, renal cell carcinoma or brain metastasis.", "sitename": "Yale Medicine", "date": "2023-08-28", "cleaned_text": "- Yale Cancer Center - Melanoma ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 8New Haven, CT 06511 Harriet Kluger, MD [Learn more about telehealth](/patient-tools/telehealth) Biography Dr. Kluger is a medical oncologist who sees patients with melanoma and renal cell carcinoma. Her research interests focus on developing new drug regimens and biomarkers predictive of response to therapies in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs an active research laboratory that studies tumor and immune cells from patients treated with novel therapies to determine mechanisms of resistance to therapy and mediators of toxicity from immune checkpoint inhibitors. The laboratory also conducts pre-clinical studies to improve treatment regimens for patients with melanoma, renal cell carcinoma or brain metastasis. Titles - Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology - Director, Yale SPORE in Skin Cancer, Yale Cancer Center - Vice Chair for Translational Research, Internal Medicine - Chief, Division of Skin and Kidney Cancer - Associate Cancer Center Director, Education, Training and Faculty Development - Deputy Section Chief, Medical Oncology Education & Training - FellowYale University School of Medicine (2002) - ResidentUniversity of New Mexico (1995) - MDTel Aviv University (1993) Additional Information [Response to \"NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors\" by Xiang-Yu Meng](http://www.ncbi.nlm.nih.gov/pubmed/37349129)Aizenbud L, Schoenfeld D, Caulfield J, Mann J, Austin M, Perdigoto A, Herold K, Kluger H. Response to \"NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors\" by Xiang-Yu Meng Journal For Ding M, Martinez-Morilla S, Aung T, Ouerghi F, Wang X, Wei W, Damsky W, Sznol M, Kluger H, Rimm D, Ishizuka J. Subsets of interferon signaling and response to immune checkpoint blockade. Journal Of Clinical Oncology 2023, 41: 9522-9522. [DOI: 10.1200/jco.2023.41.16_suppl.9522](https://doi.org/10.1200/jco.2023.41.16_suppl.9522). [Peripheral blood immune cell and cytokine profiling of patients receiving corticosteroids for immune checkpoint inhibitor-related adverse events: Steroid dose and duration.](https://doi.org/10.1200/jco.2023.41.16_suppl.e14694)Merkin R, Schoenfeld D, Djureinovic D, Austin M, Wang M, Qu R, Zhang L, Mann J, Wei W, Sun L, Aizenbud L, Destina J, Kluger H. Peripheral blood immune cell and cytokine profiling of patients receiving corticosteroids for immune checkpoint inhibitor-related adverse events: Steroid dose and duration. Journal Of Clinical Oncology 2023, 41: e14694-e14694. [DOI: 10.1200/jco.2023.41.16_suppl.e14694](https://doi.org/10.1200/jco.2023.41.16_suppl.e14694). [Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients.](http://www.ncbi.nlm.nih.gov/pubmed/37233452)Horowitch B, Lee D, Ding M, Martinez-Morilla S, Aung T, Ouerghi F, Wang X, Wei W, Damsky W, Sznol M, Kluger H, Rimm D, Ishizuka J. Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients. Clinical Cancer Research 2023, of1-of11. [PMID: T, Caulfield L, Schoenfeld D, Djureinovic D, Chiang V, Oria V, Weiss S, Olino K, Jilaveanu L, Kluger of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better](https://doi.org/10.1158/1538-7445.am2023-3287)Djureinovic D, Weiss S, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto A, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, S, Bosenberg M, Jilaveanu L, Kluger H. Abstract 3287: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily Cancer Research 2023, 83: 3287-3287. [DOI: 10.1158/1538-7445.am2023-3287](https://doi.org/10.1158/1538-7445.am2023-3287). [Abstract 2268: Single cell RNA sequencing defines dynamic immune cell subsets in serial colon and peripheral blood samples in a patient with checkpoint inhibitor-induced colitis](https://doi.org/10.1158/1538-7445.am2023-2268)Mann J, Lucca L, Austin M, Merkin R, Aizenbud L, Herold K, Robert M, Kluger H. Abstract 2268: Single cell RNA sequencing defines dynamic immune cell subsets in serial colon and peripheral blood samples in a patient with checkpoint inhibitor-induced colitis Cancer Research 2023, 83: 2268-2268. [DOI: 10.1158/1538-7445.am2023-2268](https://doi.org/10.1158/1538-7445.am2023-2268). [Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/36918220)Rizvi N, Ademuyiwa F, Cao Z, Chen H, Ferris R, Goldberg S, Hellmann M, Mehra R, Rhee I, Park J, Kluger H, Tawbi H, Sullivan R. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy Journal For ImmunoTherapy Of (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors](http://www.ncbi.nlm.nih.gov/pubmed/36918224)Kluger H, Barrett J, Gainor J, Hamid O, Hurwitz M, LaVallee T, Moss R, Zappasodi R, Sullivan R, Tawbi H, Sharon E. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors Journal For ImmunoTherapy Of with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors](http://www.ncbi.nlm.nih.gov/pubmed/36898736)Caulfield J, Aizenbud L, Perdigoto A, Meffre E, Jilaveanu D, Rich S, Aizenbud Y, Adeniran A, Herold K, Austin M, Kluger H. Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors Journal For ImmunoTherapy Of Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab](http://www.ncbi.nlm.nih.gov/pubmed/36750016)Topalian S, Sznol M, McDermott D, Kluger H, Carvajal R, Sharfman W, Brahmer J, Lawrence D, Atkins M, Powderly J, Leming P, Lipson E, Puzanov I, Smith D, Taube J, Wigginton J, Kollia G, Gupta A, Pardoll D, Sosman J, Hodi F. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab Journal Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma](http://www.ncbi.nlm.nih.gov/pubmed/36739981)Miguez S, Lee R, Chan A, Demkowicz P, Jones B, Long C, Abramson D, Bosenberg M, Sznol M, Kluger H, Goldbaum M, Francis J, Pointdujour-Lim R, Bakhoum M. Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients Cell Therapy after ICI Resistance Regardless of Definition: An Analysis of the C-144-01 Trial in Patients with Advanced Melanoma](https://doi.org/10.1016/s2666-6367(23)00359-7)Sarnaik A, Chesney J, Medina T, Hamid O, Thomas S, Wermke M, Gontcharova V, Damirchi B, Dean J, Mastellar E, Wu X, Shi W, Kluger H. 290 Response to Lifileucel Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy after ICI Resistance Regardless of Definition: An Analysis of the C-144-01 Trial in Patients with Advanced Melanoma Transplantation And Cellular Therapy 2023, 29: s223-s224. [DOI: 10.1016/s2666-6367(23)00359-7](https://doi.org/10.1016/s2666-6367(23)00359-7). [Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade](http://www.ncbi.nlm.nih.gov/pubmed/36522538)Vathiotis I, Salichos L, Martinez-Morilla S, Gavrielatou N, Aung T, Shafi S, Wong P, Jessel S, Kluger H, Syrigos K, Warren S, Gerstein M, Rimm D. Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade Npj of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure](http://www.ncbi.nlm.nih.gov/pubmed/36514045)Qu R, Kluger Y, Yang J, Zhao J, Hafler D, Krause D, Bersenev A, Bosenberg M, Hurwitz M, Lucca L, Kluger H. Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure Molecular Cancer of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma](https://doi.org/10.1016/j.iotech.2022.100140)Hassel J, Sarnaik A, Chesney J, Medina T, Hamid O, Thomas S, Wermke M, Domingo-Musibay E, Kirkwood J, Larkin J, Weber J, Fernandez A, Rodriguez J, Thomas I, Corrie P, Gontcharova V, Wu X, Shi W, Kluger H. 35MO Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144-01 study)](https://doi.org/10.1136/jitc-2022-sitc2022.0789)Sarnaik A, Lewis K, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan G, Kirkwood J, Hassel J, Orloff M, Larkin J, Weber J, Furness A, Khushalani N, Medina T, Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Chesney J. 789 Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144-01 study) 10.1136/jitc-2022-sitc2022.0789](https://doi.org/10.1136/jitc-2022-sitc2022.0789). [127 Spatial-specific to immunotherapy in melanoma patients](https://doi.org/10.1136/jitc-2022-sitc2022.0127)Aung T, Warrell J, Martinez-Morilla Chan N, Kluger H, Rimm D. 127 Spatial-specific gene signatures outperform bulk-mRNA signatures to define resistance a140-a140. [DOI: and in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab](https://doi.org/10.3389/fimmu.2022.1026964)Dey A, Austin M, Kluger H, Trunova N, Mann H, Shire N, Morgan C, Zhou D, Mugundu G. Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab](http://www.ncbi.nlm.nih.gov/pubmed/36405729)Dey A, Austin M, Kluger H, Trunova N, Mann H, Shire N, Morgan C, Zhou D, Mugundu G. Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with carcinoma after progression on immuno-oncology therapy](http://www.ncbi.nlm.nih.gov/pubmed/36328377)Choueiri T, Kluger H, George S, Tykodi S, Procopio M, Castonguay V, Folefac E, Lee C, Hotte S, Miller W, Saggi S, Lee C, Desilva H, P, Motzer R, Escudier B. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy Journal For in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance](http://www.ncbi.nlm.nih.gov/pubmed/36313654)Schoenfeld D, Merkin R, Moutafi M, Martinez S, Adeniran Kumar D, Jilaveanu L, Hurwitz M, Rimm D, Kluger H. Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic modify beta cells and cause checkpoint inhibitor-induced diabetes](http://www.ncbi.nlm.nih.gov/pubmed/35925682)Perdigoto AL, Deng S, Du KC, Kuchroo M, Burkhardt DB, Tong A, Israel G, Robert ME, Weisberg SP, Kirkiles-Smith N, Stamatouli AM, Kluger HM, MJ, Pober JS, Anderson MS, Krishnaswamy S, Herold KC. Immune cells and their inflammatory mediators modify beta cells and cause checkpoint A, Bosenberg M, Brastianos P, Cahill DP, Chen Holmen Hernando E. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities Pigment Cell Rioth M, Zhang C, Palaia J, Pisupati R, Bond C, Rosenblatt L, Broome R, Teka M, Kluger H. 1582P Real-world management of immune-related adverse events in Of Oncology 2022, 33: s1268-s1269. [DOI: investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody](https://doi.org/10.1016/j.annonc.2022.07.970)Larkin J, Dalle S, Sanmamed M, Wilson M, Hassel J, Kluger H, Orloff M, Weber J, Finckenstein F, Hari P, Jagasia M, Yin H, Shi W, Sulur G, Wu X, Gontcharova V, Lewis K. 844P Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer](http://www.ncbi.nlm.nih.gov/pubmed/35902131)Silk AW, Barker CA, Bhatia S, EA, MT, Brownell I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer Journal SOX2 as a critical regulator of metastatic outgrowth in melanoma Cellular And Molecular and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US](http://www.ncbi.nlm.nih.gov/pubmed/35771575)Ermer T, Canavan ME, Maduka RC, Li AX, Salazar MD, Zhan PL, Mase V, Kluger H, Boffa DJ. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US JAMA (TIL) cell therapy.](https://doi.org/10.1200/jco.2022.40.16_suppl.9524)Kluger H, Sarnaik A, Chesney J, Lewis K, Weber J, Gogas H, In G, Terheyden P, Lee S, Jagasia M, Masteller E, Qi R, Gontcharova V, Shi W, Fiaz R, Sulur G, Wu R, Chen G, Thomas S. Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-na\u00efve and melanoma treated with lifileucel, a tumor-infiltrating [DOI: A, C, Etts K, Kluger H, Sznol M. Clinical predictors of with 9555-9555. interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy](http://www.ncbi.nlm.nih.gov/pubmed/35354588)Baker ML, Yamamoto Y, Perazella MA, Dizman N, FP, Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy J, Hodi FS. Reply to T. Olivier et al Mahajan A, Etts K, Zhang L, Aizenbud L, Perdigoto AL, Hurwitz M, Sznol M, Herold KC, Kluger HM. Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss Qu R, Kluger Y, Chen TM, Hollander L, Safirstein R, Nelson B, Cha C, Bosenberg drives tumour rejection by promoting T cell activation European Daud AI, Hafler DA, Kluger HM, Raychaudhuri S, Sharpe AH. TCR-sequencing in cancer and a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review](http://www.ncbi.nlm.nih.gov/pubmed/35047671)Heng JS, Kim JM, Jones DK, Stoessel KM, Weiss SA, Sznol M, Kluger HM, Walter SD, Silverstein NA, Pointdujour-Lim R. Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series H. CheckMate-067: Raising the Bar for the Next Decade in Oncology Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally.](http://www.ncbi.nlm.nih.gov/pubmed/34564774)Esposito A, Jacobs D, Ariyan S, Galan A, Kluger H, Clune J, Weiss S, Tran T, Olino K. ASO Visual Abstract: Merkel Cell Carcinoma-Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally. Annals Of combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy](https://doi.org/10.1136/jitc-2021-sitc2021.389)Weiss S, Sznol M, Shaheen M, Berciano-Guerrero R, Berrocal A, E, Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy Of PK. cell immune contexture in lung cancer-associated brain metastases](http://www.ncbi.nlm.nih.gov/pubmed/34670827)Lu BY, Gupta R, Aguirre-Ducler Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases Song E, Blenman KRM, Micevic Yan Q. KDM5B promotes immune evasion Solid Tumors](https://doi.org/10.1016/j.jtho.2021.08.335)Gettinger Kluger H, Schoenfeld A, Warner A, He K, Sukari A, Thomas S, Doger B, Lee S, Haefliger S, Goldberg Z, Cacovean A, Fiaz R, Chen G, Jagasia M, Finckenstein F, Fardis M, Jimeno A. P14.05 Lymphocytes (Lifileucel, LN-144, LN-145, Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally](https://doi.org/10.1245/s10434-021-10784-7)Esposito A, Jacobs D, Ariyan S, Galan A, Kluger H, Clune J, Weiss S, Tran T, Olino K. ASO Visual Abstract: Merkel Cell Carcinoma\u2014Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally Annals Of Surgical Oncology 2021, 28: 736-737. [DOI: 10.1245/s10434-021-10784-7](https://doi.org/10.1245/s10434-021-10784-7). Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally](http://www.ncbi.nlm.nih.gov/pubmed/34494169)Esposito A, Jacobs D, Ariyan S, Galan A, Kluger H, Clune J, Weiss S, Tran T, Olino K. Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally Annals Of Have Minimal Impact on Prognosis.](http://www.ncbi.nlm.nih.gov/pubmed/34424955)Yang C, Shuch B, Kluger HM, Serrano M, Kibel AS, Humphrey PA, Adeniran AJ. Adverse Histopathologic Characteristics in Small Papillary Renal Cell Carcinomas Have Minimal Impact on Prognosis. American Journal Of intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis](http://www.ncbi.nlm.nih.gov/pubmed/34403041)Sandhu MRS, Chiang VL, Tran T, Yu JB, Weiss SA, SB, Aboian MS, Kluger HM, Mahajan A. Correction to: Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis lesions in stage III and IV melanoma: a single institute retrospective analysis](http://www.ncbi.nlm.nih.gov/pubmed/34351544)Sandhu MRS, Chiang VL, Tran T, Yu JB, Weiss S, Goldberg S, Aboian M, Kluger HM, Mahajan A. Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis Renal Cell Carcinoma Patients With Brain Metastases](http://www.ncbi.nlm.nih.gov/pubmed/34432667)Uezono H, Nam D, Kluger HM, Sznol M, Hurwitz M, Yu JB, Chiang VL. Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases American and survival in patients with metastatic non-small cell lung cancer treated with durvalumab and tremelimumab](https://doi.org/10.1158/1538-7445.am2021-489)Dey A, Austin M, Kluger H, Trunova N, Mann H, Shire N, Zhou D, Mugundu G. Abstract 489: Association between immune-mediated adverse events and survival in patients with metastatic non-small cell lung cancer treated with in patients with advanced (unresectable or metastatic) melanoma: durable duration of response at 28 month follow up](https://doi.org/10.1158/1538-7445.am2021-ct008)Chesney J, Larkin J, Kirkwood J, Weber J, Khushalani N, Lewis K, Medina T, Kluger H, Thomas S, Domingo-Musibay E, Ol\u00e1h J, Whitman E, Martin-Algarra S, Corrie P, Lutzky J, Hamid O, Shi W, Wu X, Jagasia M, Finckenstein F, Fardis cryopreserved autologous tumor infiltrating lymphocyte in patients with advanced (unresectable or metastatic) melanoma: durable duration of response at 28 month follow Cancer Research 2021, 81: ct008-ct008. [DOI: 10.1158/1538-7445.am2021-ct008](https://doi.org/10.1158/1538-7445.am2021-ct008). antigen specificity of peripherally derived T cells that infiltrate into solid tumors in patients treated with an autologous T cell therapy, PRIME IL-15 (RPTR-147)](https://doi.org/10.1158/1538-7445.am2021-lb027)Pajerowski J, Gordon W, Bardwell P, McInnis C, Hwang J, Huseni T, Agnihotri P, Francis J, Tarr C, Renoux F, Heer S, Cerreghetti-Terraneo N, Loi M, Hamilton E, Nikiforow S, Blumenschein G, Christea M, Osman K, Shields A, Kluger H, Obermair F, Pregibon D, Kisielow J, Coyle A, Skoberne M. Abstract LB027: Tracking and decoding the antigen specificity of peripherally derived T cells that infiltrate into solid tumors in patients treated with an autologous T cell therapy, PRIME Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1](http://www.ncbi.nlm.nih.gov/pubmed/34140403)Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Levit NS, Anderson G, Zelterman D, Wei W, Mahajan A, Trifan S, Sznol M, Hurwitz M, Kluger HM. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to NA, Green BF, Cottrell TR, Stein JE, Engle EL, Xu H, Ogurtsova A, Roberts C, Wang D, Nguyen P, Zhu Q, Soto-Diaz S, Loyola J, Sander IB, Wong PF, D, Wilton Roskes Eminizer M, Park S, JC, EM, Baras A, De Marzo AM, Topalian JM. Analysis of multispectral imaging with the AstroPath platform informs efficacy of transcriptomic with spatial protein information exceed the predictive value for either single modality](http://www.ncbi.nlm.nih.gov/pubmed/34050252)Vathiotis IA, Yang Z, Reeves J, Toki M, Aung TN, Wong PF, Kluger H, Syrigos KN, Warren S, Rimm DL. Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality Npj (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.](https://doi.org/10.1200/jco.2021.39.15_suppl.9505)Larkin J, Sarnaik A, Chesney J, Khushalani N, Kirkwood J, Weber J, Lewis K, Medina T, Kluger H, Thomas S, Domingo-Musibay E, Olah J, Whitman E, Martin-Algarra S, Corrie P, Lutzky J, Shi W, Wu R, Fardis M, Hamid O. Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy. with autoimmune disorders and advanced malignancies (AIM-NIVO).](https://doi.org/10.1200/jco.2021.39.15_suppl.tps2676)Dumbrava E, Dougan M, Gupta S, Cappelli L, Katsumoto T, Rahma O, Painter J, Wang Y, Suarez-Almazor M, Reid P, Wesley S, Hafler D, Bingham C, Warner B, Chung L, Ott P, Kluger H, Khosroshahi A, Tawbi H, Sharon E. A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick Whitman S, JMG, Shi W, Takamura T, Jagasia M, Qin H, Wu Chartier immunosuppressants and association with outcome: E1609 study analysis](http://www.ncbi.nlm.nih.gov/pubmed/33963015)Tarhini AA, Kang N, Lee Cohen GI, Hamid O, TM, Streicher H, Sondak adjuvant use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 CD8+ T cells and patient survival in cutaneous melanoma](http://www.ncbi.nlm.nih.gov/pubmed/33962358)Zhu G, Su H, Johnson CH, Khan SA, Kluger H, Lu L. Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/33879601)Nghiem P, Bhatia Sharfman Reddy SA, Boulmay BC, Riker A, Burgess MA, Hanks BA, Olencki T, Kendra K, Church C, Akaike T, Ramchurren N, Shinohara MM, Salim B, Taube JM, Jensen E, Kalabis M, Fling SP, Moreno B, Sharon E, Cheever MA, Topalian SL. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma Journal lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumours](https://doi.org/10.1016/s1556-0864(21)02029-3)Gettinger S, Kluger H, Schoenfeld A, Warner A, He K, Sukari A, Thomas S, de Sp\u00e9ville B, Lee S, Haefliger S, Goldberg Z, Cacovean A, Fiaz R, Chen G, Jagasia M, Finckenstein F, Fardis M, Jimeno A. 187TiP Phase of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) Jessel S, Zhang L, Raddassi K, Zhang L, Olino K, Clune J, Singer M, Kluger HM, Hafler DA. Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells Journal Of Tumor-Associated CK, Zito CR, in Melanoma by Subcellular Herold KC. Adverse events induced by immune checkpoint inhibitors Current tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity](http://www.ncbi.nlm.nih.gov/pubmed/33606757)Higgins AY, Arbune A, Soufer A, Ragheb E, Kwan JM, Lamy J, Henry M, Cuomo JR, Charifa A, Gallegos C, Hull S, Coviello JS, Bader AS, Peters DC, Huber S, Mojibian HR, Sinusas AJ, Kluger H, Baldassarre LA. Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor prognostic value to standard assessment of depth and ulceration in primary melanoma](http://www.ncbi.nlm.nih.gov/pubmed/33531581)Moore MR, Friesner ID, Rizk EM, Fullerton Mondal M, Trager MH, Mendelson K, Chikeka I, Kurc T, Gupta R, Rohr BR, Robinson EJ, Acs B, Chang R, Kluger H, Taback B, Messina J, Ferringer J, Wang J, Vanguri R, Saenger YM. Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in with Imaging Mass CytometryMultiplex Discovery with Imaging Mass Cytometry](http://www.ncbi.nlm.nih.gov/pubmed/33504554)Martinez-Morilla S, Villarroel-Espindola F, Wong Toki Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass CytometryMultiplex Discovery with Imaging for Immune Checkpoint Inhibitor Induced Acute Kidney Injury in a Patient with Concurrent Immunotherapy-Associated Diabetes: A Case Report.](http://www.ncbi.nlm.nih.gov/pubmed/33763663)Jessel S, Austin M, Kluger HM. Mycophenolate as Primary Treatment for Immune Checkpoint Inhibitor Induced Acute Kidney Injury in a Patient with Concurrent Immunotherapy-Associated Diabetes: A Case Report. Clinical [PMID: 33763663](https://pubmed.ncbi.nlm.nih.gov/33763663), [PMCID: PMC7985664](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985664). [Prolonged Complete Response of Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy.](http://www.ncbi.nlm.nih.gov/pubmed/34382032)Unlu S, Grant MJ, Gettinger S, Adeniran A, Kluger HM. Prolonged Complete Response of Early Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy. S, Goldberg SB, Kluger HM, Nguyen D, Patel A, Chiang V. Tumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States](http://www.ncbi.nlm.nih.gov/pubmed/33146688)Jacobs D, Huang H, Olino K, Weiss S, Kluger H, Judson BL, Zhang Y. Assessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United in metastatic melanoma and association with outcome on immunotherapy](http://www.ncbi.nlm.nih.gov/pubmed/33457084)Martinez-Morilla S, Zugazagoitia J, Wong PF, Kluger HM, Rimm DL. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients](https://doi.org/10.1136/jitc-2020-sitc2020.0801)Hamilton E, Nikiforow S, Bardwell P, McInnis C, Zhang J, Blumenschein G, Cristea M, Osman K, Shields A, Motta M, Bilic S, Schoenborn-Kellenberger O, Rakestraw J, Carey S, Geretti E, Sauer K, Harris T, Maniar T, Hewes B, T, Fitzgerald J, Kluger H. 801 PRIME IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients Journal For ImmunoTherapy Of Cancer 2020, 8: a850-a850. [DOI: 10.1136/jitc-2020-sitc2020.0801](https://doi.org/10.1136/jitc-2020-sitc2020.0801). - Jacobs Olino S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck 164: 1214-1221. H, Baldassarre LA. Cardiac Biventricular compared to matched extracranial metastases](http://www.ncbi.nlm.nih.gov/pubmed/32974852)Weiss SA, Zito C, Tran T, Heishima brain metastases have and density compared to Kluger H. Targeting Innate Immunity to Treat Cancer Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors.](http://www.ncbi.nlm.nih.gov/pubmed/33778814)Perdigoto AL, Tran T, Patel N, Clark P, Patell K, Stamatouli AM, Reddy V, Clune J, Herold KC, Robert ME, Kluger HM. Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors. Clinical Oncology, Case Reports 2020, 3 [PMID: 33778814](https://pubmed.ncbi.nlm.nih.gov/33778814), [PMCID: PMC7993656](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993656). [Abstract 3095: Combination of spatial protein data with bulk transcriptional profiling of the same cohort shows relationships between RNA and protein and facilitates combined predictive signatures](https://doi.org/10.1158/1538-7445.am2020-3095)Vathiotis I, Reeves J, Toki M, Wong P, Kluger H, Aung T, Syrigos K, Warren S, Rimm D. Abstract 3095: Combination of spatial protein data with bulk transcriptional profiling of the same cohort shows relationships between RNA and protein and facilitates combined predictive signatures Cancer Research 2020, 80: cytometry](https://doi.org/10.1158/1538-7445.am2020-2001)Martinez-Morilla S, Villarroel-Espindola F, Wong P, Kluger H, Toki M, Aung T, Pelekanou V, Bourke-Martin D. Abstract 2001: Biomarker discovery in immunotherapy-treated melanoma patients phase 1b study patients with autoimmune disorders and advanced malignancies (AIM-NIVO)](https://doi.org/10.1158/1538-7445.am2020-ct249)Ileana Dumbrava E, Suarez-Almazor M, Painter J, Johanns T, Dougan M, Cappelli L, Wang Y, Bingham C, Gupta S, Warner B, Rahma O, Naidoo J, Ott P, Hafler D, Kluger H, Khosroshahi A, Naqash R, Chung L, Katsumoto T, Kummar S, Tawbi H, Sharon E. Abstract CT249: A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO) Cancer Research 2020, 80: Idoate MA, Lu B, J, RS, Gil-Bazo I. PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Cancer 2020, 26: 4186-4197. [PMID: 32354698](https://pubmed.ncbi.nlm.nih.gov/32354698), [DOI: 10.1158/1078-0432.ccr-20-0798](https://doi.org/10.1158/1078-0432.ccr-20-0798). - Oria Zhu H, Deng G, Zito C, Rane C, Zhang S, Weiss S, Tran T, Adeniran A, Zhang F, Zhou J, Kluger Y, Bosenberg M, Kluger H, Jilaveanu L. 19. PLEKHA5 REGULATES TUMOR Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)](http://www.ncbi.nlm.nih.gov/pubmed/32439653)Diab A, Tannir NM, Bentebibel U, Aung S, Fanton C, Rizwan A, Iacucci E, Liao Y, Bernatchez C, Hurwitz ME, Cho DC. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02) Cancer 2020, JM, Farhadian S, Kluger HM, Kluger Y. Impact of healthcare worker shift scheduling on workforce preservation during the COVID-19 pandemic Infection Control And Hospital Epidemiology 2020, 41: 1443-1445. Metastases: Melanoma infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.](https://doi.org/10.1200/jco.2020.38.15_suppl.10006)Sarnaik A, Khushalani N, Chesney J, Lewis K, Medina T, Kluger H, Thomas S, Domingo Musibay E, Pavlick A, Whitman E, Martin-Algarra S, Corrie P, Lutzky J, Hamid O, Wu R, Shi W, Fardis M, Weber J, Larkin J, Kirkwood J. Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies. Journal Of Clinical Oncology study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.](https://doi.org/10.1200/jco.2020.38.15_suppl.3094)Shapira R, Weber J, Geva R, Sznol M, Kluger H, Wong D, Liang B. A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies. Journal Of Clinical Oncology 2020, treatment-refractory advanced renal cell carcinoma (aRCC).](https://doi.org/10.1200/jco.2020.38.15_suppl.5007)Choueiri T, Kluger H, George S, Tykodi S, Kuzel S, Procopio M, Castonguay V, Folefac E, Lee C, Hotte S, Miller W, Saggi S, Gold D, Motzer R, Escudier B. FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma phase Ib study autoimmune disorders and advanced malignancies (AIM-NIVO).](https://doi.org/10.1200/jco.2020.38.15_suppl.tps3158)Ileana Dumbrava E, Suarez-Almazor M, Painter J, Johanns T, Dougan M, Cappelli L, Bingham C, Wang Y, Gupta S, Warner B, Rahma O, Naidoo J, Ott P, Hafler D, Kluger H, Khosroshahi A, Katsumoto T, Kummar S, Sharon E, Tawbi H. A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). anti-programmed cell death locally advanced basal cell carcinoma in treatment-naive patients: A case series](http://www.ncbi.nlm.nih.gov/pubmed/32613057)Ligtenberg KG, Hu JK, Damsky K, Kluger H, Clune J, Cowper SE, Panse G, Leventhal J, Weiss SA. Neoadjuvant anti-programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case Vaisman A, Abu Ahmad Y, Zohar Y, Zhang T, Lee JS, Lazar I, Sheikh Khalil S, Feiler Y, Kluger C, Brown K, Ruppin of eIF2 by RNF4 Promotes Melanoma Tumorigenesis and Therapy infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies - independent review committee data update](https://doi.org/10.1136/lba2019.18)Sarnaik A, Khushalani N, Chesney J, Kluger H, Curti B, Lewis K, Medina T, Thomas S, Pavlick A, Whitman E, Algarra S, Corrie P, Hamid O, Lutzky J, Olah J, Weber J, Larkin J, Shi W, DiTrapani K, Qin H, Mirgoli M, Wu R, Takamura T, Fardis M, Kirkwood J. P865 Safety & efficacy lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies - independent review committee data update Journal For ImmunoTherapy Of Cancer 2020, 8: a12. [DOI: 10.1136/lba2019.18](https://doi.org/10.1136/lba2019.18). [Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 Clune J, Ariyan S, Cha C, Weiss SA, Kluger HM, Sznol M. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce](http://www.ncbi.nlm.nih.gov/pubmed/32238470)Kluger HM, Tawbi HA, Ascierto ML, MK, CG, Gulley TM, Le DT, Hubbard-Lucey VM, Papadimitrakopoulou VA, Postow Rubin EH, Sharon E, JM, Topalian SL, Zappasodi R, Sznol M, Sullivan RJ. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce Journal Architecture, Rather Than Typing of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis](http://www.ncbi.nlm.nih.gov/pubmed/32101890)Yang C, Shuch B, Kluger H, Humphrey PA, Adeniran AJ. High WHO/ISUP Grade and Unfavorable Architecture, Rather Than Typing of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis The American Journal Of Surgical Pathology 2020, 44: 582-593. [PMID: 32101890](https://pubmed.ncbi.nlm.nih.gov/32101890), Tawbi H. Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy 2020, 1421-1454. [DOI: 10.1007/978-3-030-05070-2_65](https://doi.org/10.1007/978-3-030-05070-2_65). [Leptomeningeal disease in melanoma patients: An and future directions](http://www.ncbi.nlm.nih.gov/pubmed/31916400)Glitza IC, Smalley KSM, Brastianos PK, Davies MA, McCutcheon Arrington JA, Evernden BR, Smalley I, Eroglu Z, Khushalani N, Margolin MB, A, Forsyth P. Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions Pigment Cell & Melanoma Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis](http://www.ncbi.nlm.nih.gov/pubmed/33147119)Tran TT, Gallezot Zito Huang H, Huttner A, Kluger HM, Chiang VL, Carson R. [11C]Methionine and [11C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis Molecular Plasma Renalase, and Their Association With All-Cause Mortality](http://www.ncbi.nlm.nih.gov/pubmed/32154458)Chang J, Guo X, Rao V, Gromisch ES, Chung S, Kluger HM, Cha C, Gorelick F, Testani J, Safirstein R, Crowley S, Peixoto AJ, Desir GV. Identification of Two Forms of Human Plasma Renalase, and Their Association With All-Cause Mortality Kidney International HM. Complications associated with immunotherapy for Rosenberg AS, Rongioletti F, Pilloni L, D'Hallewin S, Gueorguieva mass [PMID: 31697431](https://pubmed.ncbi.nlm.nih.gov/31697431), 10.1111/cup.13610](https://doi.org/10.1111/cup.13610). Zito CR, Oria VO, Rane CK, Zhang S, Weiss SA, Tran T, Zhang F, Zhou MW, M, Tran T, Jilaveanu L, Cohen J, Hegde U, Wei W, Mahajan A, Goldberg S, Chiang V, Weiss S. RBTT-07. A PHASE 2 TRIAL OF PEMBROLIZUMAB AND BEVACIZUMAB IN H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death](http://www.ncbi.nlm.nih.gov/pubmed/31636101)Kulkarni PM, Robinson EJ, PF, Acs B, Rizk EM, Yang C, Mondal M, Moore MR, Osman I, Phelps R, Horst BA, Chen ZS, Ferringer T, Rimm DL, Wang J, Saenger YM. Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death Clinical Cancer Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab](http://www.ncbi.nlm.nih.gov/pubmed/31358540)Hamid O, Molinero L, Bolen CR, Sosman M, O'Hear C, Chen DS, Hegde PS, Hodi FS. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab patients (pts) with advanced melanoma: Phase III LEAP-003 study](https://doi.org/10.1093/annonc/mdz255.063)Eggermont A, Carlino P, Arance A, Daud A, O'Day S, Taylor M, Smith A, Rodgers A, Moreno B, Diede S, Kluger H. 1375TiP Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study Annals [DOI: 10.1093/annonc/mdz255.063](https://doi.org/10.1093/annonc/mdz255.063). [Closed system RT-qPCR as diagnostic test for immunotherapy outcome in metastatic melanoma](http://www.ncbi.nlm.nih.gov/pubmed/31533832)Gupta S, McCann L, Chan YGY, Lai EW, Wei W, Wong PF, Smithy JW, Weidler J, Rhees B, Bates M, Kluger HM, Rimm DL. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma Journal For Immunotherapy-Treated Patients Using Digital Spatial Profiling](http://www.ncbi.nlm.nih.gov/pubmed/31189645)Toki MI, Merritt CR, PF, Smithy JW, Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling Clinical Measure of the Effects of Immune Checkpoint Inhibition\u2014A Pooled Analysis of Patients With Advanced Melanoma](http://www.ncbi.nlm.nih.gov/pubmed/31498030)Regan MM, Werner L, Rao S, Gupte-Singh K, Hodi MB, McDermott DF. Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition\u2014A Pooled Analysis of Patients With Advanced Melanoma Journal Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With SB, Kluger HM, Chiang VLS. Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors International Journal Of 1113-1118. Nolte A, Ghabili K, Cheng M, Liu S, Chiang V, Kluger H, Hurwitz M, Shuch B. Brain Metastasis From Renal-Cell Carcinoma: An and implications for treatment with immune therapy](http://www.ncbi.nlm.nih.gov/pubmed/31362777)Tran TT, Mahajan A, Chiang VL, HM. Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy Journal For ImmunoTherapy Of Cancer with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma](http://www.ncbi.nlm.nih.gov/pubmed/31340861)Klemen ND, Wang M, Feingold PL, Cooper K, Pavri Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, Clune J, Ariyan S, Salem RR, Weiss SA, Kluger HM, Sznol M, Cha C. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma Journal melanoma](http://www.ncbi.nlm.nih.gov/pubmed/31337426)Wong JW, Zelterman HM, Rimm DL. Multiplex immunotherapy outcome in metastatic melanoma transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasis](https://doi.org/10.1158/1538-7445.sabcs18-4552)Wingrove E, Liu Z, Nguyen D, Arnal-Estape A, Patel K, Melnick M, Politi K, Valiente M, Kluger H, Chiang V. Abstract 4552: BMX-Seq as a new resource for deciphering the transcriptomic hallmarks of tumor plasticity transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasis](https://doi.org/10.1158/1538-7445.am2019-4552)Wingrove E, Liu Z, Nguyen D, Arnal-Estape A, Patel K, Melnick M, Politi K, Valiente M, Kluger H, Chiang V. Abstract 4552: BMX-Seq as a new resource for deciphering the transcriptomic hallmarks of tumor plasticity and stromal in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC)](https://doi.org/10.1158/1538-7445.sabcs18-ct089)Kluger H, Weiss S, Olszanski A, Schuchter L, Linette G, Garland L, Iannotti N, Johnson M, Avsar E, Srivastava M, Trifan O, Edelman M. Abstract CT089: Phase Ib/II CD40 agonistic antibody APX005M in subjects with metastatic melanoma (M) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC)](https://doi.org/10.1158/1538-7445.am2019-ct089)Kluger H, Weiss S, Olszanski A, Schuchter L, Linette G, Garland L, Iannotti N, Johnson M, Avsar E, Srivastava M, Trifan O, Edelman M. Abstract CT089: Phase Ib/II CD40 agonistic antibody APX005M in subjects with metastatic melanoma (M) or non-small panel and immunotherapy outcome in metastatic melanoma](https://doi.org/10.1158/1538-7445.sabcs18-3142)Gupta S, McCann L, Chan Y, Lai E, Wong P, Smithy J, Weidler J, Rhees B, Bates M, CD274, in panel and immunotherapy outcome in metastatic melanoma](https://doi.org/10.1158/1538-7445.am2019-3142)Gupta S, McCann L, Chan Y, Lai E, Wong P, Smithy J, Weidler J, Rhees B, Bates M, CD274, in panel and immunotherapy metastatic 10.1158/1538-7445.am2019-3142](https://doi.org/10.1158/1538-7445.am2019-3142). Jilaveanu L, Turner Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors Journal For ImmunoTherapy Novel IL2R-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors](http://www.ncbi.nlm.nih.gov/pubmed/30988166)Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker M, Biomarker Analysis of NKTR-214, a Novel IL2R-Biased Cytokine, in Patients with Advanced or Metastatic Solid nivolumab.](https://doi.org/10.1200/jco.2019.37.15_suppl.2623)Hurwitz M, Cho D, Balar M, Kluger H, Bernatchez C, Fanton C, Iacucci E, Liu Y, Nguyen T, Overwijk W, Zalevsky J, Tagliaferri M, Hoch U, Diab A. Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and Of Clinical Damsky W, Kluger H, Bosenberg M. Evaluating the role of the COX2/PGE2 pathway in anti-melanoma immunity. Journal Of Clinical Oncology 2019, 37: e14114-e14114. [DOI: 10.1200/jco.2019.37.15_suppl.e14114](https://doi.org/10.1200/jco.2019.37.15_suppl.e14114). [Functional profile and clinical of tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases.](https://doi.org/10.1200/jco.2019.37.15_suppl.2066)Lu B, Gupta R, Stewart T, Kluger H, Jilaveanu L, Schalper K, Goldberg S. Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.](https://doi.org/10.1200/jco.2019.37.15_suppl.2518)Sarnaik A, Khushalani N, Chesney J, Kluger H, Curti B, Lewis K, Thomas S, Whitman E, Hamid O, Lutzky J, Pavlick A, Weber J, Larkin J, Barton D, Yung L, Suzuki S, Fardis M, Kirkwood J. Safety and efficacy of cryopreserved autologous infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1. Journal Of Clinical Oncology 2019, 37: 2518-2518. States phase randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-2b for resected high-risk melanoma.](https://doi.org/10.1200/jco.2019.37.15_suppl.9504)Tarhini A, Lee S, Hodi F, Rao U, Cohen G, Hamid O, Hutchins L, Sosman J, Kluger H, Sondak V, Koon H, Lawrence D, Kendra K, Minor D, Lee C, Albertini M, Flaherty L, Petrella T, Kirkwood J. United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-2b for combined nivolumab (NIVO) and ipilimumab (IPI) in with J, Wolchok J, Callahan M, Kluger H, Postow M, Segal N, Lesokhin A, Balogh A, Re S, Sznol M. Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with with advanced melanoma previously exposed to anti-PD-1/PD-L1 agents: Phase 2 LEAP-004 Daud A, Eggermont A, Hauschild A, Kluger H, Taylor M, Smith A, Chen K, Krepler C, Diede S, O'Day S. Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma previously exposed to anti-PD-1/PD-L1 agents: Phase 2 LEAP-004 tps9594-tps9594. Tawbi H. Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy 2019, 1-34. [DOI: 10.1007/978-3-319-46029-1_65-1](https://doi.org/10.1007/978-3-319-46029-1_65-1). [Multiplex Quantitative Melanoma](http://www.ncbi.nlm.nih.gov/pubmed/30617133)Wong K, Zelterman D, HM, Lymphocytes and Immunotherapy Zhu L, Kluger HM, Chiang VL, Nguyen DX. Transcriptomic Hallmarks of Tumor Plasticity and Stromal ArnalEstape A, Melnick M, Politi K, Monteiro C, Zhu L, Valiente M, Kluger H, Chiang V, Nguyen D. Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.](https://doi.org/10.1200/jco.2019.37.8_suppl.136)Sarnaik A, Thomas S, Davar D, Kirkwood J, Kluger H, Lutzky J, Wilson M, Pavlick A, Curti B, Whitman E, Phan G, Ernstoff M, Takamura K, Barton D, Suzuki S, Karyampudi L, Samberg N, Fardis M, Chesney J. Safety and of cryopreserved autologous infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy. Journal Of Clinical Oncology 2019, 37: 136-136. [DOI: 10.1200/jco.2019.37.8_suppl.136](https://doi.org/10.1200/jco.2019.37.8_suppl.136). GV, Tawbi HA, Goldberg SB, Chiang VL. Reply to A. Shinde et al Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley Forsyth PA, Davies MA, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities Pigment Cell & Melanoma Kluger H, Weiss S, Chow J, Stoessel K, Kombo N, Del Priore L, Pointdujour-Lim R. Ophthalmic Adverse and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy](http://www.ncbi.nlm.nih.gov/pubmed/30726175)Nghiem P, Bhatia Reddy SA, Boulmay BC, Riker AI, T, Margolin K, Lundgren LM, Soni A, Ramchurren SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Moreno B, Sharon E, Cheever MA, Topalian SL. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy Journal patients with Merkel cell carcinoma receiving anti-PD-1 therapy](http://www.ncbi.nlm.nih.gov/pubmed/30482247)Miller NJ, Church CD, Fling SP, Kulikauskas R, Ramchurren Shinohara MM, Kluger S, Lundgren L, Cheever MA, Topalian SL, Nghiem P. Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy Journal For ImmunoTherapy Of With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial](http://www.ncbi.nlm.nih.gov/pubmed/30407895)Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, Perrotti E, Anderson G, Ralabate A, Kluger Y, Wei W, Goldberg SB, Jilaveanu LB. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial Journal A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management](http://www.ncbi.nlm.nih.gov/pubmed/30399387)Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management Journal Of The American Academy Of Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma](https://doi.org/10.1016/j.ijrobp.2018.06.134)Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma International Journal Oncology Biology Physics 2018, 102: [DOI: 10.1016/j.ijrobp.2018.06.134](https://doi.org/10.1016/j.ijrobp.2018.06.134). [Results Phase II Trial of Cabozantinib in Patients with Non-small-cell Carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/30528315)Hellerstedt BA, Vogelzang NJ, Kluger HM, Yasenchak CA, Aftab DT, Ramies DA, Gordon MS, Lara P. Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma Clinical Lung 20: 74-81.e1. Syed J, Nguyen KA, McGillivray P, Adeniran A, Humphrey P, Dancik GM, Kluger Y, Liu Z, Kluger H, Shuch B. Genomic Heterogeneity and the Small Renal K, 3638: tumor-infiltrating lymphocytes and by NanoString Digital Spatial Profiling technology and quantitative immunofluorescence](https://doi.org/10.1158/1538-7445.am2018-3621)Toki M, Wong P, Kluger H, Liu Y, Merritt C, Ong G, Warren S, Beechem J, Rimm D. Abstract 3621: High-plex immune marker spatial profiling quantitation by NanoString Digital Spatial Profiling technology and quantitative Research 2018, 78: 3621-3621. [DOI: 10.1158/1538-7445.am2018-3621](https://doi.org/10.1158/1538-7445.am2018-3621). [Abstract CT169: A phase II, multicenter study to assess the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-144) for treatment of patients with metastatic melanoma](https://doi.org/10.1158/1538-7445.am2018-ct169)Sarnaik A, Curti B, Davar D, Hamid O, Lutzky J, Wilson M, Kluger H, Chesney J, Kim K, Phan G, Thomas S, Whitman E, Larsen B, Suzuki S, Samberg N, Gorbatchevsky I, Fardis M, Kirkwood J. Abstract CT169: A phase II, multicenter study to assess the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-144) for treatment of patients Quandt PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. Collateral Damage: Insulin-Dependent Diabetes Induced With and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.](https://doi.org/10.1200/jco.2018.36.15_suppl.2009)Goldberg S, Gettinger S, Mahajan A, Herbst Chiang R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W, Chiang V, Kluger H. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. Oncology 2018, 36: 2009-2009. [DOI: 10.1200/jco.2018.36.15_suppl.2009](https://doi.org/10.1200/jco.2018.36.15_suppl.2009). [Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with non-small lung cancer (NSCLC) or melanoma.](https://doi.org/10.1200/jco.2018.36.15_suppl.9099)Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) edema and blood vessel characteristics in brain metastases and implications for treatment with immune therapy.](https://doi.org/10.1200/jco.2018.36.15_suppl.9572)Tran T, Jilaveanu L, Mahajan A, Goldberg S, Nguyen D, Chiang V, Kluger H. Perilesional edema and blood vessel characteristics in brain metastases and implications for treatment with immune therapy. Journal Of Oncology advanced solid tumors: Preliminary phase 1/2 results of PIVOT.](https://doi.org/10.1200/jco.2018.36.15_suppl.3006)Diab A, Hurwitz M, Cho D, Papadimitrakopoulou V, Curti B, Tykodi S, Puzanov I, Ibrahim N, Tolaney S, Tripathy D, Gao J, Siefker-Radtke A, Clemens W, Tagliaferri M, Gettinger S, Kluger H, N. NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT. Journal Of Clinical Oncology 2018, 36: 3006-3006. [DOI: 10.1200/jco.2018.36.15_suppl.3006](https://doi.org/10.1200/jco.2018.36.15_suppl.3006). [Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy.](https://doi.org/10.1200/jco.2018.36.15_suppl.9506)Nghiem P, Bhatia S, Lipson Sharfman Kudchadkar Friedlander P, Brohl A, Daud A, Kluger H, Reddy S, Burgess M, Hanks B, Olencki T, Boulmay B, Lundgren L, Ramchurren N, Homet Moreno B, Sharon E, Cheever M, Topalian S. Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy. Journal Of Clinical Oncology 2018, 36: 9506-9506. [DOI: 10.1200/jco.2018.36.15_suppl.9506](https://doi.org/10.1200/jco.2018.36.15_suppl.9506). - Lu B, Gupta R, Ribeiro M, Stewart T, Chiang V, Contessa J, Adeniran A, Kluger H, Jilaveanu L, Schalper K, Goldberg S. PD-L1 expression and tumor-infiltrating lymphocytes in lung cancer brain 36: e24116-e24116. [DOI: 10.1200/jco.2018.36.15_suppl.e24116](https://doi.org/10.1200/jco.2018.36.15_suppl.e24116). [A phase 2, multicenter efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of melanoma.](https://doi.org/10.1200/jco.2018.36.15_suppl.tps9595)Sarnaik A, Curti B, Davar D, Kirkwood J, Hamid O, Lutzky J, Wilson M, Kluger H, Whitman E, Phan G, Thomas S, Lewis K, Arkenau H, Chesney J, Larsen B, Gorbatchevsky I, Suzuki S, Samberg N, Fardis M. A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients Clinical Sznol M, Schalper K, \"Kevin\" Kim H. Safety and feasibility of immuno-cryotherapy. Journal Of Clinical Oncology 2018, 36: 34-34. [DOI: 10.1200/jco.2018.36.5_suppl.34](https://doi.org/10.1200/jco.2018.36.5_suppl.34). - Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, Bacchiocchi A, Kluger H, Wei W, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM. Early B cell changes predict autoimmunity following combination immune checkpoint blockade Journal Of Clinical 128: K, J, Asmellash SG, Roder J, Roder H. A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805](http://www.ncbi.nlm.nih.gov/pubmed/29066509)Jilaveanu LB, Puligandla M, Weiss SA, Wang X, KT, Boeke M, Neumeister V, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas N, Kluger HM. Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805 Clinical H, Klymenko O, Kim H, Feng Y, Zhang T, Han JY, Murao A, Snipas SJ, Jilaveanu L, Brown K, Kluger H, Zhang H, Iwai K, Ronai Z. SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study](http://www.ncbi.nlm.nih.gov/pubmed/29040030)Callahan MK, Kluger H, Postow Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study Journal O'Day S, Hodi FS, Pavlick AC, Kluger H, Oxborough A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS. Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United and resistance to immunotherapy in cancer patients.](http://www.ncbi.nlm.nih.gov/pubmed/32120553)Weber JS, Woods D, Laino Roder H, Roder J, Blackmon K, Sullivan R. Proteomic and T cell biomarkers identify sensitivity and resistance to immunotherapy in cancer patients. Annals Of Oncology : Official Journal Of The European Society For Medical of anti-CTLA-4 treatment is associated with improved intracranial control](http://www.ncbi.nlm.nih.gov/pubmed/28916225)An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu Wang Mahajan A, Welsh JB, MA, Hwu P, EP, Brown early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors](http://www.ncbi.nlm.nih.gov/pubmed/28223273)Kluger HM, Zito CR, Turcu G, Baine M, Zhang H, Adeniran A, Sznol M, Y, Chen L, Cohen JV, Jilaveanu LB. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors Clinical Cancer response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients](http://www.ncbi.nlm.nih.gov/pubmed/28595336)Sanmamed Fusco Gonzalez Perez G, Alfaro C, Mart\u00edn-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung BRAF and NRAS melanoma](https://doi.org/10.1158/1538-7445.am2017-ct003)Sullivan R, Janku F, Li B, Wong D, Sosman J, Keedy V, Buchbinder E, Tolcher A, Varghese A, Hyman D, Flaherty K, Ribas A, Carvajal R, Wang-Gillam A, Kluger H, Patel M, P, Varterasian M, Welsch D, in on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.](https://doi.org/10.1200/jco.2017.35.15_suppl.2545)Bernatchez C, Haymaker C, Hurwitz M, Kluger H, Tetzlaff M, Jackson N, Gergel I, Tagliaferri M, Zalevsky J, Hoch U, Fanton C, Iacucci E, Aung S, Imperiale M, Liao E, Bentebibel S, Tannir N, Hwu P, Sznol M, Diab A. Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy. Journal Of Clinical Oncology 2017, 35: 2545-2545. [DOI: IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors.](https://doi.org/10.1200/jco.2017.35.15_suppl.e14040)Diab A, Tannir N, Bernatchez C, Haymaker M, Gergel I, Tagliaferri M, Zalevsky J, Hoch U, Aung S, Imperiale M, Cho D, Tykodi S, Puzanov I, Kluger H, Hurwitz M, Hwu P, Sznol M. A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors. Journal Of Clinical Oncology 2017, 10.1200/jco.2017.35.15_suppl.e14040](https://doi.org/10.1200/jco.2017.35.15_suppl.e14040). - Weiss Haas N, Wang X, Zito C, Boeke M, Neumeister V, Manola J, DiPaola R, Kluger H. Microvessel density as a prognostic marker in high-risk renal cell carcinoma. Journal Of Clinical Oncology 2017, 35: anti-PD1 antibody nivolumab H, Callahan M, Weise M, Rawls T, Vitale L, Halim A, Keler T, Davis T, Rizvi N. Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in 2017, heavily pretreated patients with metastatic therapy.](https://doi.org/10.1200/jco.2017.35.15_suppl.3045)Sarnaik Veerapathran A, Simpson-Abelson M, Lotze M, Larsen B, Fischkoff S, Suzuki S, Wang L, Mirgoli M, Fardis M, Curti B. Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.](https://doi.org/10.1200/jco.2017.35.15_suppl.9500)Tarhini A, Lee S, Hodi F, Rao U, Cohen G, Hamid O, Hutchins L, Sosman J, Kluger H, Sondak V, Koon H, Lawrence D, Kendra K, Minor D, Lee C, Albertini M, Flaherty L, Petrella T, Kirkwood J. A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms. Journal Clinical [DOI: [Nuclear IRF-1 expression as a mechanism assess \"Capability\" to express PD-L1 and response to PD-1 therapy in metastatic melanoma](http://www.ncbi.nlm.nih.gov/pubmed/28331615)Smithy JW, Moore LM, Pelekanou PF, Sznol M, Kluger HM, Rimm DL. Nuclear IRF-1 expression as a mechanism to assess \"Capability\" to express PD-L1 and response to PD-1 therapy in metastatic melanoma Journal Goldberg SB, Kluger HM, Chiang VL. Comparing available criteria for measuring brain metastasis response memory phenotype in individual melanoma metastases.](https://doi.org/10.1200/jco.2017.35.7_suppl.3)Dhodapkar K, Boddupalli C, Bar N, Kadaveru K, Krauthammer Pornputtapong N, Mai Z, Ariyan S, Narayan D, Kluger H, Deng Y, Verma R, Das R, Bacchiocchi A, Halaban R, Sznol M, Dhodapkar M. Distinct dominant T-cell receptors with a tissue resident memory phenotype in individual activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma.](https://doi.org/10.1200/jco.2017.35.6_suppl.454)Hurwitz M, Diab A, Bernatchez C, Haymaker C, Kluger H, Tetzlaff M, Gergel U, Zalevsky J, Hwu P, Sznol M, Tannir N. Effect of NKTR-214 on the number and activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma. Journal Of Oncology 2017, 35: 454-454. R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells](http://www.ncbi.nlm.nih.gov/pubmed/28018970)Boddupalli CS, Bar N, Kadaveru K, Krauthammer M, Pornputtapong N, Mai Z, Ariyan S, Narayan D, Kluger H, Deng Y, Verma R, Das R, Bacchiocchi A, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM. Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-Macdonald M. Immunomodulatory Activity of Nivolumab in Metastatic Renal S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM. Melanoma central nervous system metastases: current approaches, challenges, and opportunities Pigment Cell & Kluger HM. Evolving Immunotherapy Approaches for Renal Cell Carcinoma 57. [PMID: 27475806](https://pubmed.ncbi.nlm.nih.gov/27475806), [DOI: 10.1007/s11912-016-0542-9](https://doi.org/10.1007/s11912-016-0542-9). [Abstract combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): across multiple immune pathways without H, Yellin M, Rawls T, Vitale L, Halim A, Davis T, Keler T. Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward [DOI: 10.1158/1538-7445.am2016-ct023](https://doi.org/10.1158/1538-7445.am2016-ct023). [Abstract CT096: Clinical activity, immune and viral correlates of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma](https://doi.org/10.1158/1538-7445.am2016-ct096)Nghiem P, Bhatia S, Lipson E, Kudchadkar R, Miller N, Daud A, Fling K, Olencki T, Reddy S, Shantha E, Sharfman W, Sharon E, Shinohara M, Thompson J, Yearley J, Topalian S, Cheever M. Abstract CT096: Clinical activity, immune and viral correlates of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma Cancer Research 2016, 76: ct096-ct096. [DOI: 10.1158/1538-7445.am2016-ct096](https://doi.org/10.1158/1538-7445.am2016-ct096). [Renalase Expression by Growth through a STAT3-Mediated Mechanism](http://www.ncbi.nlm.nih.gov/pubmed/27197188)Hollander L, Guo X, Velazquez H, Chang J, Safirstein R, Kluger H, Cha C, Desir G. Renalase Expression by Melanoma and Tumor-Associated Macrophages Promotes Tumor Growth through a Shuch B. MET Inhibition in Clear Cell Renal Cell Carcinoma Journal Of checkpoint therapy affect the early radiographic response of melanoma brain metastases JB, Kluger HM, Chiang VL. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain non-small-cell lung cancer and untreated brain metastases: early analysis of non-randomised, open-label, phase Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 AO, Chiang A, Gettinger S, Goldberg S, Kluger HM, Chiang VL. Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases S, Odunsi G, Pandite L, Holdich T, Norry E, Binder-Scholl G, Amado NY-ESO-1 c259 T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing Clinical Oncology 2016, 34: tps3101-tps3101. [DOI: 10.1200/jco.2016.34.15_suppl.tps3101](https://doi.org/10.1200/jco.2016.34.15_suppl.tps3101). [Phase I study and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of (VEGF-A) (sVEGFR2) in plasma](http://www.ncbi.nlm.nih.gov/pubmed/27103123)Li J, Kluger H, Devine L, Lee JJ, Kelly WK, Rink L, Saif MW. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) A, T, Pardoll DM, EM, Sharfman Pembrolizumab in Advanced Merkel-Cell Carcinoma New England 27093365](https://pubmed.ncbi.nlm.nih.gov/27093365), Merino M, Said J, Adeniran A, Nawaf C, Xie Z, Boeke M, Valera B. MP71-12 GENOMIC CHARACTERIZATION OF SARCOMATOID TRANSFORMATION IN CLEAR CELL RENAL CELL CARCINOMA Investigative Urology 2016, 195: e920. [DOI: 10.1016/j.juro.2016.02.1458](https://doi.org/10.1016/j.juro.2016.02.1458). - Cohen JV, Systemic for the Treatment of Brain PMC4881844](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881844), JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi Pantuck AJ, Kluger HM, K, Lifton RP, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma Proceedings Of The National Academy Of Sciences Of The United States Of America Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma](http://www.ncbi.nlm.nih.gov/pubmed/26307133)Wilson MA, Zhao Copy Number Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Kluger H, Xie Z, Nawaf C, Merino M, Valera V, Pantuck A, Said J, A, Lifton R, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Journal Of Clinical Oncology 2016, 34: 509-509. [DOI: 10.1200/jco.2016.34.2_suppl.509](https://doi.org/10.1200/jco.2016.34.2_suppl.509). [Demonstration treated with RS. Demonstration differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery. 29296434](https://pubmed.ncbi.nlm.nih.gov/29296434), [PMCID: PMC5658871](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658871). Lau Feng Fukuda MN, Perlina A, Donn D, Jilaveanu L, ATF2 promotes melanoma Smith Kluger H, Molina AM, Gulati P, A, Ahlers CM, Cardarelli PM, Cohen LJ. necrosis after radiosurgical treatment of brain metastases?](http://www.ncbi.nlm.nih.gov/pubmed/26544782)Colaco RJ, Martin P, Kluger HM, Yu JB, Chiang VL. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors](http://www.ncbi.nlm.nih.gov/pubmed/26448928)Shuch Falbo Adeniran A, Kluger Y, HM, Jilaveanu LB. MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Clinical trials in melanoma patients with brain metastases Pigment Cell A, Evans P, Pornputtapong N, Wu C, McCusker JP, Ma S, Cheng E, Straub R, Serin M, Bosenberg M, Ariyan sequencing in NF1 and metastatic renal cell carcinoma specimens](http://www.ncbi.nlm.nih.gov/pubmed/26317902)Baine MK, Turcu G, Zito Kluger HM, Jilaveanu LB. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell Samples Baine DL, Chen Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable cell carcinoma with emphasis on subtyping](http://www.ncbi.nlm.nih.gov/pubmed/26239624)Alomari AK, Nettey OS, Singh D, Kluger H, Adeniran AJ. Clinicopathological and immunohistochemical characteristics of papillary renal cell carcinoma with emphasis on Human 46: 1418-1426. [PMID: 26239624](https://pubmed.ncbi.nlm.nih.gov/26239624), [DOI: 10.1016/j.humpath.2015.06.006](https://doi.org/10.1016/j.humpath.2015.06.006). - Kluger H, Liu X. At the front line of combating cancer: an interview with Harriet Kluger, MD. The Yale Journal Of Biology And Medicine 2015, 88: 187-9. [PMID: 26029017](https://pubmed.ncbi.nlm.nih.gov/26029017), [PMCID: patients with metastatic non-small cell lung cancer with untreated brain metastases.](https://doi.org/10.1200/jco.2015.33.15_suppl.8035)Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Tsiouris A, Vortmeyer A, Jilaveanu L, Speaker S, Madura M, Rowen E, Gerrish H, Knapp-Perry E, Yao X, Chiang V, Kluger H. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. Journal Clinical Oncology 2015, 33: 8035-8035. J, Vortmeyer A, Jilaveanu L, Ralabate A, Rivera A, Burke M, Hegbe U, Cohen J, Yao X, Speaker S, Madura M, Knapp-Perry E, Mahajan A, Chiang V. Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases. carcinoma (mRCC): Association of biomarkers with clinical outcomes.](https://doi.org/10.1200/jco.2015.33.15_suppl.4500)Choueiri T, Fishman M, Escudier B, McDermott D, Kluger H, Stadler W, Perez-Gracia J, McNeel D, Curti B, Harrison M, Plimack E, Appleman L, Fong L, Drake C, Young T, Chasalow S, Ross-Macdonald P, Simon J, Walker D, Sznol M. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. Journal Of Clinical Oncology 2015, 33: 4500-4500. [DOI: 10.1200/jco.2015.33.15_suppl.4500](https://doi.org/10.1200/jco.2015.33.15_suppl.4500). [Phase 2 vemurafenib in active melanoma brain metastases (coBRIM-B).](https://doi.org/10.1200/jco.2015.33.15_suppl.tps9088)Yee M, Lin Y, Gorantla V, Butterfield Kluger Chapman P, Gangadhar R, Schuchter L, Tarhini A, Kirkwood J, Tawbi H. Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain Biomarker and Potential Mediator of Melanoma Brain and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab](http://www.ncbi.nlm.nih.gov/pubmed/25800770)McDermott DF, Drake A, McDonald D, Sankar V, Sosman JA, Atkins MB. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab Journal Of S, Kluger H, Lupsa B, Herold KC. Precipitation of Autoimmune Diabetes Herzog EL, Lee CG, Peng X, Lee CM, Chen X, Rockwell S, Koo JS, Kluger H, Herbst RS, Sznol M, Elias JA. Role Chitinase 3-like-1 and Semaphorin 7a in Repair JF, Powell SN, Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB KM. Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In M, Kluger H, Choi J. Pregabalin for the treatment of painful hand-foot skin reaction distant sites: A useful marker of primary and metastatic renal cell carcinoma?](http://www.ncbi.nlm.nih.gov/pubmed/25315900)Barr ML, Jilaveanu expression in renal tumours and distant sites: A useful marker of primary and metastatic renal cell carcinoma? Journal Of Clinical melanomas: The Yale University Spitzoid Neoplasm Repository experience, 1991 to 2008](http://www.ncbi.nlm.nih.gov/pubmed/25308882)Lott JP, Wititsuwannakul JJ, Ariyan S, Narayan D, HH, R. with Spitzoid malignant melanomas: The Yale University Spitzoid Neoplasm Repository experience, 1991 to 2008 Journal Of The American Academy Of with BRAF and NRAS mutations and response to treatment with carboplatin, paclitaxel and sorafenib](https://doi.org/10.1158/1538-7445.am2014-933)Wilson M, Zhao F, Khare D'Andrea K, Rimm D, Kirkwood J, Kluger H, Lee S, Schuchter L, Flaherty K, Nathanson K. Abstract 933: Copy number changes are associated with BRAF and NRAS mutations and response to treatment With Advanced Melanoma](http://www.ncbi.nlm.nih.gov/pubmed/25267741)Ott PA, Pavlick AC, Kluger H, Kim KB, Boasberg PD, Simantov R, Crowley E, Green JA, Hawthorne T, Davis TA, Sznol M, Hwu P. Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients Necrosis Following Gamma Knife Radiosurgery in the Treatment of Brain Metastases](https://doi.org/10.1016/j.ijrobp.2014.05.1035)Colaco R, Martin P, Bond J, Bindra R, Contessa J, Kluger H, Yu J, Chiang V. Systemic Treatment and Radiation Necrosis Following Gamma Knife Radiosurgery in the Treatment of Brain Metastases International Journal Of Radiation Oncology Biology Physics 2014, 90: s310. [DOI: 10.1016/j.ijrobp.2014.05.1035](https://doi.org/10.1016/j.ijrobp.2014.05.1035). [Survival, response duration, and nivolumab (NIVO, anti-PD-1, M, Kluger H, Callahan M, Postow M, Gordon R, Segal N, Rizvi N, Lesokhin A, Atkins M, Kirkwood J, Burke M, Ralabate A, Rivera A, Kronenberg S, Agunwamba B, Feely W, Hong Q, Krishnan S, Gupta A, Wolchok J. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, ipilimumab (IPI) HM. NY-ESO-1 as a potential immunotherapeutic target in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib](http://www.ncbi.nlm.nih.gov/pubmed/24714776)Wilson MA, of Somatic Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.](https://doi.org/10.1200/jco.2014.32.15_suppl.4532)Kluger H, Halabi S, Solomon N, Jilaveanu L, Zito C, Sznol J, Nixon A, Rini B, Small E, George D. Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB 10.1200/jco.2014.32.15_suppl.4532](https://doi.org/10.1200/jco.2014.32.15_suppl.4532). activity of nivolumab and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.](https://doi.org/10.1200/jco.2014.32.15_suppl.5012)Choueiri T, Fishman M, Escudier B, Kim J, Kluger H, Stadler W, Perez-Gracia J, McNeel D, Curti B, Harrison M, Plimack E, Appleman L, Fong L, Drake C, Cohen L, Srivastava S, Jure-Kunkel M, Hong Q, Kurland J, Sznol M. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. 2014, 32: 5012-5012. [DOI: 10.1200/jco.2014.32.15_suppl.5012](https://doi.org/10.1200/jco.2014.32.15_suppl.5012). [Long-term survival of (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.](https://doi.org/10.1200/jco.2014.32.15_suppl.9002)Hodi F, Sznol M, Kluger H, McDermott D, Carvajal R, Lawrence D, Topalian S, Atkins M, Powderly J, Sharfman W, Puzanov I, Smith D, Leming P, Lipson E, Taube J, Anders R, Horak C, Kollia G, Gupta A, Sosman J. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I Oncology 2014, 32: 9002-9002. [DOI: 10.1200/jco.2014.32.15_suppl.9002](https://doi.org/10.1200/jco.2014.32.15_suppl.9002). [Survival, response duration, nivolumab (NIVO, anti-PD-1, M, Kluger H, Callahan M, Postow M, Gordon R, Segal N, Rizvi N, Lesokhin A, Atkins M, Kirkwood J, Burke M, Ralabate A, Rivera A, Kronenberg S, Agunwamba B, Feely W, Hong Q, Krishnan S, Gupta A, Wolchok J. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, ipilimumab (IPI) 2014, 32: lba9003-lba9003. [DOI: [Induction of NY-ESO-1 to the Dendritic Cell Receptor DEC-205](http://www.ncbi.nlm.nih.gov/pubmed/24739759)Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, Kluger H, Tejwani J, Ramakrishna V, Crocker A, Vitale L, Yellin M, Davis T, Keler T. Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor 10.1186/1476-4598-13-45](https://doi.org/10.1186/1476-4598-13-45). [Survival, Durable Remission, Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab](http://www.ncbi.nlm.nih.gov/pubmed/24590637)Topalian SL, Sznol M, McDermott DF, JA, Hodi FS. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab Journal Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases](http://www.ncbi.nlm.nih.gov/pubmed/24563671)Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, Chen L, Kluger HM. PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases Journal HM. area as a predictor of sorafenib response in metastatic renal cell carcinoma Cancer Cell 14: 4. 24423208](https://pubmed.ncbi.nlm.nih.gov/24423208), and Survival in Metastatic Melanoma Following Radiosurgery](https://doi.org/10.1016/j.ijrobp.2013.06.717)Rutter C, Giesen E, Yu J, Bindra R, Kluger H, Chiang V. Influence of BRAF and NRAS Mutations on Distant Intracranial Recurrence and Survival in Metastatic Melanoma Following Radiosurgery International Journal Of inhibits metastasis of melanoma](http://www.ncbi.nlm.nih.gov/pubmed/24037523)Scortegagna M, Ruller C, Feng Y, Lazova Kluger Li JL, SK, Rickert R, Genetic inactivation pharmacological delays Glazer PM. Radiation sensitivity and sensitization in melanoma Pigment Cell KT, Lee SJ, Kluger HM. Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).](https://doi.org/10.1200/jco.2013.31.18_suppl.cra9006)Sznol M, Kluger H, Hodi F, McDermott Carvajal R, Lawrence D, Topalian S, Atkins M, Powderly J, Sharfman W, Puzanov I, Smith D, Wigginton J, Kollia G, Gupta A, Sosman J. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza M. Nivolumab plus Ipilimumab in Advanced Melanoma New ONO-4538) in combination with ipilimumab in advanced melanoma (MEL).](https://doi.org/10.1200/jco.2013.31.15_suppl.9012)Wolchok J, Kluger H, Callahan M, Postow M, Gordon R, Segal N, Rizvi N, Lesokhin A, Reed K, Burke M, Caldwell A, Kronenberg S, Agunwamba B, Feely W, Hong Q, Horak C, Korman A, Wigginton J, Gupta A, Sznol M. Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). Journal Of Clinical Oncology 2013, 31: 9012-9012. [DOI: nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.](https://doi.org/10.1200/jco.2013.31.15_suppl.4514)Drake C, McDermott D, Sznol M, Choueiri T, Kluger H, Powderly J, Smith D, Sankar V, Gutierrez A, Wigginton J, Kollia G, Gupta A, Atkins M. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up. Oncology of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).](https://doi.org/10.1200/jco.2013.31.15_suppl.9010)Hamid O, Sosman J, Lawrence D, Sullivan R, Ibrahim N, Kluger H, Boasberg P, Flaherty K, Hwu P, Ballinger M, Mokatrin A, Kowanetz M, Chen D, Hodi F. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). Journal Of a phase II randomized discontinuation trial (RDT).](https://doi.org/10.1200/jco.2013.31.15_suppl.9094)Daud A, Kluger H, Edelman G, Gordon M, Schimmoller F, Weitzman A, Samuel T, Moussa A, Flaherty K, Shapiro G. Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT). Journal Of Clinical Oncology 2013, 31: 9094-9094. [DOI: 10.1200/jco.2013.31.15_suppl.9094](https://doi.org/10.1200/jco.2013.31.15_suppl.9094). [Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).](https://doi.org/10.1200/jco.2013.31.15_suppl.cra9006)Sznol M, Kluger H, Hodi F, McDermott Carvajal R, Lawrence D, Topalian S, Atkins M, Powderly J, Sharfman W, Puzanov I, Smith D, Wigginton J, Kollia G, Gupta A, Sosman J. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; Yushak M, Kluger in 2013, F, Kluger Y, Camp RL, Kluger HM. Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors BMC Clinical Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Annals Of Oncology : Official Journal Of The European Society For Medical / ESMO 2013, Camp RL, Kluger HM. Vascularity of primary and metastatic renal cell carcinoma specimens Journal Of Translational Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma Annals Of S, Narayan D, Bacchiocchi A, Cheng E, Xu F, Li P, Kluger H, Halaban R, Kluger Y. Integrated analysis of tumor samples sheds light on tumor heterogeneity. The Yale Journal Of Biology And Medicine 2012, HM. Drug targets and predictive biomarkers in the management of metastatic melanoma Pharmacogenomics And BH, Evans P, Bacchiocchi A, McCusker J, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan A, Holman EC, M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Melanoma: Lessons Learned ipilimumab era and the possibility of longer survival.](http://www.ncbi.nlm.nih.gov/pubmed/22702482)Knisely JP, Yu JB, Flanigan J, Sznol melanoma brain metastases in the ipilimumab era and the possibility of longer survival. Journal a phase II randomized discontinuation trial (RDT).](https://doi.org/10.1200/jco.2012.30.15_suppl.7514)Hellerstedt B, Edelman G, Vogelzang N, Kluger H, Yasenchak C, Shen X, Ramies D, Gordon M, Lara P. Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT). Journal Of Clinical phase II randomized discontinuation trial (RDT).](https://doi.org/10.1200/jco.2012.30.15_suppl.8531)Gordon M, Kluger H, Shapiro G, Kurzrock R, Edelman G, Samuel T, Moussa A, Ramies D, Laird A, Schimmoller F, Shen X, Daud A. Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT). Journal Of Clinical Oncology 2012, 30: 8531-8531. [DOI: 10.1200/jco.2012.30.15_suppl.8531](https://doi.org/10.1200/jco.2012.30.15_suppl.8531). - Wilson D'Andrea K, Rimm D, Kirkwood J, Kluger H, Lee S, Flaherty K, Nathanson K. Abstract 5557: Mutation analysis of melanoma tumor samples from ECOG 2603 clinical trial Kluger HM, Camp RL. CD70 expression patterns in renal cell Cells](http://www.ncbi.nlm.nih.gov/pubmed/22355357)Zito Camp R, Kluger HM, Chao HH. Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer the Nucleus while Blocking Its Apoptotic Function at Mitochondria](http://www.ncbi.nlm.nih.gov/pubmed/22304920)Lau E, Kluger H, Varsano T, ZA. PKC Promotes Oncogenic Functions of ATF2 in the Nucleus while Blocking Its Apoptotic Function Kluger HM. Chapter One Vertical Pathway Targeting in Cancer Therapy 2012, 65: 1-26. [PMID: 22959021](https://pubmed.ncbi.nlm.nih.gov/22959021), [DOI: 10.1016/b978-0-12-397927-8.00001-4](https://doi.org/10.1016/b978-0-12-397927-8.00001-4). Heller KN, Hoos A, Sznol M. Case Report: Response to Ipilimumab in a Patient With HIV With Metastatic Melanoma Flanigan J, Sznol M, Yu J. Outcomes of Melanoma Brain Metastasis Management with Gamma Knife Radiosurgery +/- Ipilimumab International Journal target of rapamycin (mTOR) in renal cell cancer](http://www.ncbi.nlm.nih.gov/pubmed/21834980)Elfiky AA, Aziz SA, Conrad PJ, Siddiqui S, Hackl W, Maira M, Robert CL, Kluger HM. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer Journal Of VL, Kluger HM. Melanoma Brain Metastases: Is It Time to Reassess the Bias? Current Problems Ubiquitin-binding Domains*](http://www.ncbi.nlm.nih.gov/pubmed/21659512)Scortegagna M, Subtil T, Qi J, Kim H, W, Gu W, Kluger H, Ronai ZA. USP13 Y, Sznol M, Ariyan S, Molinaro A, Halaban R. Plasma Markers for Identifying Patients with Metastatic Melanoma RL, Rimm DL, Dudek A, Sznol M, Kluger HM. In vitro studies of dasatinib, its targets and predictors of sensitivity Pigment Cell Conrad P, Aziz S, Camp R, Schwartz B, Chen C, Kelly W, Kluger H. C-met as a therapeutic target using ARQ 197 in renal cell carcinoma. Journal Of Clinical Oncology 2011, 29: 360-360. [DOI: 10.1200/jco.2011.29.7_suppl.360](https://doi.org/10.1200/jco.2011.29.7_suppl.360). W, Kluger J, Lau E, Kallenberg DM, Jeong H, Eroshkin A, Bennett DC, Chin L, Bosenberg M, Jones N, Ronai ZA. A Role for ATF2 in Regulating RL, Rimm DL, Conrad P, Kluger HM. Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma LB, A, Sznol M. A phase 2 trial G, Jerusalem G, Gordon M, Kluger H, Moussa A, Ron I, Schimmoller F, Shen X, Daud A. 398 Phase 2 results of XL184 in a cohort of patients (pts) with advanced melanoma European Journal Of Cancer Supplements 2010, 8: [Benefits of Y, Camp Y. Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032](http://www.ncbi.nlm.nih.gov/pubmed/20630094)Rubinstein JC, Sznol M, Pavlick Bacchiocchi A, Kluger HM, Narayan D, Halaban R. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032 Journal Y, Kluger H, Stern DF. Centrosomal Chk2 in DNA damage responses and cell in with advanced melanoma.](https://doi.org/10.1200/jco.2010.28.15_suppl.8525)Hamid O, Sznol M, Pavlick A, Kluger H, Kim K, Boasberg P, Simantov R, Davis T, Crowley E, Hwu P. Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with 2010, Bepler G, Camp R, Kluger H. Abstract 1787: Dual targeting of PI3K and mTOR results in synergistic growth inhibition JM, Aziz S, Camp RL, Rimm DL, HM. DL. Melanoma Prognostic Model Using Tissue Microarrays and Genetic and biologic therapies for melanoma: do M, Camp RL, Rimm DL, Kluger HM. C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas Clinical and therapeutic target in breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/19717535)Nadler Y, Gonz\u00e1lez AM, Camp RL, Rimm factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer Annals of prognosis in breast cancer](https://doi.org/10.1200/jco.2009.27.15_suppl.11013)Giltnane J, Rapp J, Moeder C, Camp R, Kluger H, Molinaro A, Rimm D. Construction of a five-marker protein-based model for stage-independent assessment of prognosis in breast cancer Journal Of Clinical Oncology 2009, 27: 11013-11013. [DOI: 10.1200/jco.2009.27.15_suppl.11013](https://doi.org/10.1200/jco.2009.27.15_suppl.11013). [A phase I study of sunitinib combination with sirolimus in adults with advanced refractory malignancies](https://doi.org/10.1200/jco.2009.27.15_suppl.3554)Li J, Kluger H, Saif M, Murren J, Lee J, Kelly W, Rink L, Devine L, Sznol M. A phase I study of sunitinib in combination with sirolimus in adults with advanced refractory Journal Kluger Ritacco J, Adrada C, Phouyaphone N, Southard N, Sznol M. A phase II trial of dasatinib in advanced melanoma Journal Of glycoprotein (GPNMB) advanced melanoma](https://doi.org/10.1200/jco.2009.27.15_suppl.9032)Hwu P, Sznol M, Pavlick A, Kluger H, Kim K, Boasberg P, Sanders D, Simantov R, Crowley E, Hamid O. A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) (ADC), in a phase (Ph) I study of patients (pts) with advanced melanoma](https://doi.org/10.1200/jco.2009.27.15_suppl.9063)Sznol M, Hamid O, Hwu P, Kluger H, Hawthorne T, Crowley E, Simantov A. Pharmacokinetics (PK) of CR011-vcMMAE, an antibody-drug conjugate (ADC), in a phase (Ph) I study of patients (pts) with advanced melanoma Journal Of Clinical Oncology 2009, 27: 9063-9063. [DOI: 10.1200/jco.2009.27.15_suppl.9063](https://doi.org/10.1200/jco.2009.27.15_suppl.9063). - Aziz SA, Davies Pick Zito C, Jilaveanu L, Camp RL, Rimm DL, Kluger Y, Kluger HM. Phosphatidylinositol-3-Kinase as a Therapeutic Target in Sorafenib in Melanoma Patients Treated with Carboplatin, Paclitaxel by HuR in breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/19151756)Woo HH, Zhou Y, Yi X, David CL, Zheng W, Gilmore-Hebert M, Kluger HM, Ulukus EC, Baker T, Stoffer JB, Chambers SK. Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in Oncogene 2009, 1176-1186. [PMID: 19151756](https://pubmed.ncbi.nlm.nih.gov/19151756), [DOI: 10.1038/onc.2008.469](https://doi.org/10.1038/onc.2008.469). - Borden EC, Kluger H, Crowley J. Apoptosis: a clinical perspective Nature Reviews Drug Discovery 2008, 7: [PMID: 19065702](https://pubmed.ncbi.nlm.nih.gov/19065702), Rimm DL, Kluger HM, Kluger Y. Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer Clinical Cancer Research based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells](http://www.ncbi.nlm.nih.gov/pubmed/18626467)Kluger HM, Siddiqui SF, Angeletti C, Sznol M, Kelly WK, Molinaro AM, Camp RL. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial 2008, 88: 962-972. [PMID: 18626467](https://pubmed.ncbi.nlm.nih.gov/18626467), Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer](http://www.ncbi.nlm.nih.gov/pubmed/18528297)Acquavella N, Kluger J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M. Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell benign melanocytic lesions](http://www.ncbi.nlm.nih.gov/pubmed/18552823)Rothberg BE, Moeder CB, Kluger H, Halaban R, GF, Lazar A, Prieto V, Duncan LM, Rimm DL. non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer Kluger HM, Davis S, Subtil A, Meltzer P, Krajewski S, Jones N, Ronai Z. Suppressor role of activating transcription factor 2 (ATF2) in skin cancer Proceedings Of The National Academy Of Sciences Of The United States Of America 2008, 105: 1674-1679. [PMID: 18227516](https://pubmed.ncbi.nlm.nih.gov/18227516), MM, Kluger HM. Assessing Expression of Apoptotic Markers Using Large Microarrays 2008, 414: 83-93. 18175814](https://pubmed.ncbi.nlm.nih.gov/18175814), [DOI: 10.1007/978-1-59745-339-4_8](https://doi.org/10.1007/978-1-59745-339-4_8). - McCarthy M, Kluger H. Assessing Expression of Apoptotic Markers Using Large Cohort Tissue Microarrays 2008, 83-93. [DOI: 10.1007/978-1-59745-339-4_8](https://doi.org/10.1007/978-1-59745-339-4_8). - Pick E, McCarthy M, Kluger H. Assessing Expression of Apoptotic Markers Using Large Cohort Tissue Microarrays 2007, 414: 83-94. [DOI: 10.1385/1-59745-339-0:83](https://doi.org/10.1385/1-59745-339-0:83). - McCarthy MM, Lazova R, Camp RL, Rimm DL, Kluger HM. HSP90 as a marker of Decreased Survival in Cancer](http://www.ncbi.nlm.nih.gov/pubmed/17804730)Bromberg KD, Kluger HM, Delaunay A, Abbas S, DiVito KA, Z. Increased Expression of the E3 Ubiquitin Ligase RNF5 Is Associated with Decreased Survival in (RCC) based on the expression of VEGF and its receptors on tumor cells and microvessels: Identification of subsets with distinct patterns of expression, microvessel density, and outcome](https://doi.org/10.1200/jco.2007.25.18_suppl.15503)Camp R, Siddiqui S, Kelly W, Uchio E, Kluger H. Classification of renal cell carcinoma (RCC) based on the expression of VEGF and its receptors on tumor cells and microvessels: Identification of subsets with distinct patterns of expression, microvessel density, and outcome Journal Of Clinical Oncology 2007, 25: 15503-15503. [DOI: 10.1200/jco.2007.25.18_suppl.15503](https://doi.org/10.1200/jco.2007.25.18_suppl.15503). - Mehnert J, McCarthy M, Aziz S, Sznol M, Flaherty K, Camp R, Rimm D, Kluger H. VEGF, VEGFR1, and VEGFR2 25: 8520-8520. [DOI: 10.1200/jco.2007.25.18_suppl.8520](https://doi.org/10.1200/jco.2007.25.18_suppl.8520). - Aziz S, Pick-Golan E, McCarthy M, Flaherty K, Camp R, Rimm D, Kluger H. Assessment of PI3 kinase as a druggable target 2007, RL, Rimm DL, Kluger HM. High HSP90 Expression Is Associated with Decreased Survival in Breast Cancer Cancer Research HM, Alvero AB, Sznol M, Ariyan Camp RL, Rimm with R. Rab33A: Characterization, Expression, and Suppression by Epigenetic Modification Divito K, Camp R, Rimm D, Mor G. XIAP is highly expressed in melanoma and is associated with chemotherapy resistance Journal Of Clinical Oncology 2006, 24: 8008-8008. [DOI: 10.1200/jco.2006.24.18_suppl.8008](https://doi.org/10.1200/jco.2006.24.18_suppl.8008). Halaban R, Berger KT, Camp RL, Lazova R, Rimm DL, Kluger HM. Expression of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptors 1 and 2 in from JR, Kluger HM. Metastatic myoepithelial carcinoma of the vulva Tuck D. Association between pathways in regulatory networks Annual International Conference Of The IEEE Engineering In Medicine And Biology Society (EMBC) 2006, Camp RL, Rimm DL, Kluger HM. Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer 16033835](https://pubmed.ncbi.nlm.nih.gov/16033835), [DOI: Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive Disease](http://www.ncbi.nlm.nih.gov/pubmed/15994930)Kluger HM, Lev D, Kluger Y, McCarthy MM, Kiriakova G, Camp RL, Rimm DL, Price JE. Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive Disease Cancer Research 2005, 65: 5578-5587. [PMID: 15994930](https://pubmed.ncbi.nlm.nih.gov/15994930), [DOI: 10.1158/0008-5472.can-05-0108](https://doi.org/10.1158/0008-5472.can-05-0108). Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/15930343)Harigopal M, Berger AJ, Camp RL, Rimm DL, Kluger HM. Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer Clinical Cancer Research 2005, 11: 4083-4089. [PMID: 15930343](https://pubmed.ncbi.nlm.nih.gov/15930343), [DOI: 10.1158/1078-0432.ccr-04-2191](https://doi.org/10.1158/1078-0432.ccr-04-2191). Sznol M, Rimm D, Kluger H. Expression and prognostic value of TRAIL receptors R1 and R2 in early stage breast cancer Journal Of Clinical Oncology 2005, 23: 9528-9528. [DOI: 10.1200/jco.2005.23.16_suppl.9528](https://doi.org/10.1200/jco.2005.23.16_suppl.9528). [Automated Quantitative Analysis Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome](http://www.ncbi.nlm.nih.gov/pubmed/15574789)Berger AJ, Camp RL, DiVito KA, Kluger HM, Halaban R, Rimm DL. Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome 2004, 64: 8767-8772. 15574789](https://pubmed.ncbi.nlm.nih.gov/15574789), [DOI: 10.1158/0008-5472.can-04-1384](https://doi.org/10.1158/0008-5472.can-04-1384). [Automated Quantitative Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma](http://www.ncbi.nlm.nih.gov/pubmed/15574790)Divito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM. Automated Quantitative Analysis of Tissue Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma Cancer Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, Wu T, Niinobe M, Yoshikawa K, Hannigan GE, Halaban R. Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to K, Zhao H, Ariyan S, Lin A, Kluger H, Berger A, Cheng E, Trombetta E, Wu T, Halaban R, Niinobe M, Yoshikawa K, Hannigan G. Expression profiling reveals novel pathways in the transformation of Melanocytes to Melanomas. Pigment Cell Melanoma [DOI: 10.1111/j.1600-0749.2004.00175_12.x](https://doi.org/10.1111/j.1600-0749.2004.00175_12.x). - Divito M, Camp Berger A, Rimm D, Kluger H. Evaluation of Bcl-2 expression in melanoma - A tissue microarray study Journal Clinical 22: 7515-7515. [DOI: 10.1200/jco.2004.22.14_suppl.7515](https://doi.org/10.1200/jco.2004.22.14_suppl.7515). - Divito Camp Berger A, Rimm D, Kluger H. Evaluation of Bcl-2 expression in melanoma - A tissue microarray study Journal Clinical 22: 7515-7515. - CheloucheLev Berger AJ, Rimm DL, Price JE. Bcrystallin as a marker of lymph node involvement in breast carcinoma Cancer 2004, 100: 2543-2548. [PMID: 15197794](https://pubmed.ncbi.nlm.nih.gov/15197794), [DOI: 10.1002/cncr.20304](https://doi.org/10.1002/cncr.20304). [Her2/neu is not a commonly expressed therapeutic target in melanoma - a large cohort tissue microarray study](http://www.ncbi.nlm.nih.gov/pubmed/15179190)Kluger HM, DiVito K, Berger AJ, Halaban R, Ariyan S, Camp RL, Rimm DL. Her2/neu is not a commonly expressed therapeutic target in melanoma - a large cohort tissue microarray microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model Laboratory [PMID: 14767486](https://pubmed.ncbi.nlm.nih.gov/14767486), [DOI: 10.1038/labinvest.3700044](https://doi.org/10.1038/labinvest.3700044). Price J. Alpha B crystallin, a novel marker for breast cancer metastasis Annals Colony-Stimulating Factor-1 Receptor Expression Is Associated with Poor Outcome in Breast Cancer by Large Cohort Tissue Microarray Analysis](http://www.ncbi.nlm.nih.gov/pubmed/14734466)Kluger HM, Dolled-Filhart Colony-Stimulating Factor-1 Receptor Expression Is Associated with Poor Outcome in Breast Cancer by Large Cohort Tissue Microarray Analysis Clinical Cancer Research 2004, 10: 173-177. [PMID: 14734466](https://pubmed.ncbi.nlm.nih.gov/14734466), [DOI: 10.1158/1078-0432.ccr-0699-3](https://doi.org/10.1158/1078-0432.ccr-0699-3). [Subcellular localization of 2 in melanoma specimens predicts patient survival.](http://www.ncbi.nlm.nih.gov/pubmed/14678960)Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, Rimm DL. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Research 2003, 63: 8103-7. [PMID: 14678960](https://pubmed.ncbi.nlm.nih.gov/14678960). - Yale Cancer Center - Melanoma ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 8New Haven, CT 06511 Biography Dr. Kluger is a medical oncologist who sees patients with melanoma and renal cell carcinoma. Her research interests focus on developing new drug regimens and biomarkers predictive of response to therapies in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs an active research laboratory that studies tumor and immune cells from patients treated with novel therapies to determine mechanisms of resistance to therapy and mediators of toxicity from immune checkpoint inhibitors. The laboratory also conducts pre-clinical studies to improve treatment regimens for patients with melanoma, renal cell carcinoma or brain metastasis. Titles - Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology - Director, Yale SPORE in Skin Cancer, Yale Cancer Center - Vice Chair for Translational Research, Internal Medicine - Chief, Division of Skin and Kidney Cancer - Associate Cancer Center Director, Education, Training and Faculty Development - Deputy Section Chief, Medical Oncology Education & Training - FellowYale University School of Medicine (2002) - ResidentUniversity of New Mexico (1995) - MDTel Aviv University (1993) Additional Information [Response to \"NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors\" by Xiang-Yu Meng](http://www.ncbi.nlm.nih.gov/pubmed/37349129)Aizenbud L, Schoenfeld D, Caulfield J, Mann J, Austin M, Perdigoto A, Herold K, Kluger H. Response to \"NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors\" by Xiang-Yu Meng Journal For Ding M, Martinez-Morilla S, Aung T, Ouerghi F, Wang X, Wei W, Damsky W, Sznol M, Kluger H, Rimm D, Ishizuka J. Subsets of interferon signaling and response to immune checkpoint blockade. Journal Of Clinical Oncology 2023, 41: 9522-9522. [DOI: 10.1200/jco.2023.41.16_suppl.9522](https://doi.org/10.1200/jco.2023.41.16_suppl.9522). [Peripheral blood immune cell and cytokine profiling of patients receiving corticosteroids for immune checkpoint inhibitor-related adverse events: Steroid dose and duration.](https://doi.org/10.1200/jco.2023.41.16_suppl.e14694)Merkin R, Schoenfeld D, Djureinovic D, Austin M, Wang M, Qu R, Zhang L, Mann J, Wei W, Sun L, Aizenbud L, Destina J, Kluger H. Peripheral blood immune cell and cytokine profiling of patients receiving corticosteroids for immune checkpoint inhibitor-related adverse events: Steroid dose and duration. Journal Of Clinical Oncology 2023, 41: e14694-e14694. [DOI: 10.1200/jco.2023.41.16_suppl.e14694](https://doi.org/10.1200/jco.2023.41.16_suppl.e14694). [Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients.](http://www.ncbi.nlm.nih.gov/pubmed/37233452)Horowitch B, Lee D, Ding M, Martinez-Morilla S, Aung T, Ouerghi F, Wang X, Wei W, Damsky W, Sznol M, Kluger H, Rimm D, Ishizuka J. Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients. Clinical Cancer Research 2023, of1-of11. [PMID: T, Caulfield L, Schoenfeld D, Djureinovic D, Chiang V, Oria V, Weiss S, Olino K, Jilaveanu L, Kluger of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better](https://doi.org/10.1158/1538-7445.am2023-3287)Djureinovic D, Weiss S, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto A, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, S, Bosenberg M, Jilaveanu L, Kluger H. Abstract 3287: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily Cancer Research 2023, 83: 3287-3287. [DOI: 10.1158/1538-7445.am2023-3287](https://doi.org/10.1158/1538-7445.am2023-3287). [Abstract 2268: Single cell RNA sequencing defines dynamic immune cell subsets in serial colon and peripheral blood samples in a patient with checkpoint inhibitor-induced colitis](https://doi.org/10.1158/1538-7445.am2023-2268)Mann J, Lucca L, Austin M, Merkin R, Aizenbud L, Herold K, Robert M, Kluger H. Abstract 2268: Single cell RNA sequencing defines dynamic immune cell subsets in serial colon and peripheral blood samples in a patient with checkpoint inhibitor-induced colitis Cancer Research 2023, 83: 2268-2268. [DOI: 10.1158/1538-7445.am2023-2268](https://doi.org/10.1158/1538-7445.am2023-2268). [Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/36918220)Rizvi N, Ademuyiwa F, Cao Z, Chen H, Ferris R, Goldberg S, Hellmann M, Mehra R, Rhee I, Park J, Kluger H, Tawbi H, Sullivan R. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy Journal For ImmunoTherapy Of (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors](http://www.ncbi.nlm.nih.gov/pubmed/36918224)Kluger H, Barrett J, Gainor J, Hamid O, Hurwitz M, LaVallee T, Moss R, Zappasodi R, Sullivan R, Tawbi H, Sharon E. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors Journal For ImmunoTherapy Of with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors](http://www.ncbi.nlm.nih.gov/pubmed/36898736)Caulfield J, Aizenbud L, Perdigoto A, Meffre E, Jilaveanu D, Rich S, Aizenbud Y, Adeniran A, Herold K, Austin M, Kluger H. Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors Journal For ImmunoTherapy Of Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab](http://www.ncbi.nlm.nih.gov/pubmed/36750016)Topalian S, Sznol M, McDermott D, Kluger H, Carvajal R, Sharfman W, Brahmer J, Lawrence D, Atkins M, Powderly J, Leming P, Lipson E, Puzanov I, Smith D, Taube J, Wigginton J, Kollia G, Gupta A, Pardoll D, Sosman J, Hodi F. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab Journal Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma](http://www.ncbi.nlm.nih.gov/pubmed/36739981)Miguez S, Lee R, Chan A, Demkowicz P, Jones B, Long C, Abramson D, Bosenberg M, Sznol M, Kluger H, Goldbaum M, Francis J, Pointdujour-Lim R, Bakhoum M. Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients Cell Therapy after ICI Resistance Regardless of Definition: An Analysis of the C-144-01 Trial in Patients with Advanced Melanoma](https://doi.org/10.1016/s2666-6367(23)00359-7)Sarnaik A, Chesney J, Medina T, Hamid O, Thomas S, Wermke M, Gontcharova V, Damirchi B, Dean J, Mastellar E, Wu X, Shi W, Kluger H. 290 Response to Lifileucel Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy after ICI Resistance Regardless of Definition: An Analysis of the C-144-01 Trial in Patients with Advanced Melanoma Transplantation And Cellular Therapy 2023, 29: s223-s224. [DOI: 10.1016/s2666-6367(23)00359-7](https://doi.org/10.1016/s2666-6367(23)00359-7). [Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade](http://www.ncbi.nlm.nih.gov/pubmed/36522538)Vathiotis I, Salichos L, Martinez-Morilla S, Gavrielatou N, Aung T, Shafi S, Wong P, Jessel S, Kluger H, Syrigos K, Warren S, Gerstein M, Rimm D. Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade Npj of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure](http://www.ncbi.nlm.nih.gov/pubmed/36514045)Qu R, Kluger Y, Yang J, Zhao J, Hafler D, Krause D, Bersenev A, Bosenberg M, Hurwitz M, Lucca L, Kluger H. Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure Molecular Cancer of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma](https://doi.org/10.1016/j.iotech.2022.100140)Hassel J, Sarnaik A, Chesney J, Medina T, Hamid O, Thomas S, Wermke M, Domingo-Musibay E, Kirkwood J, Larkin J, Weber J, Fernandez A, Rodriguez J, Thomas I, Corrie P, Gontcharova V, Wu X, Shi W, Kluger H. 35MO Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144-01 study)](https://doi.org/10.1136/jitc-2022-sitc2022.0789)Sarnaik A, Lewis K, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan G, Kirkwood J, Hassel J, Orloff M, Larkin J, Weber J, Furness A, Khushalani N, Medina T, Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Chesney J. 789 Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144-01 study) 10.1136/jitc-2022-sitc2022.0789](https://doi.org/10.1136/jitc-2022-sitc2022.0789). [127 Spatial-specific to immunotherapy in melanoma patients](https://doi.org/10.1136/jitc-2022-sitc2022.0127)Aung T, Warrell J, Martinez-Morilla Chan N, Kluger H, Rimm D. 127 Spatial-specific gene signatures outperform bulk-mRNA signatures to define resistance a140-a140. [DOI: and in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab](https://doi.org/10.3389/fimmu.2022.1026964)Dey A, Austin M, Kluger H, Trunova N, Mann H, Shire N, Morgan C, Zhou D, Mugundu G. Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab](http://www.ncbi.nlm.nih.gov/pubmed/36405729)Dey A, Austin M, Kluger H, Trunova N, Mann H, Shire N, Morgan C, Zhou D, Mugundu G. Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with carcinoma after progression on immuno-oncology therapy](http://www.ncbi.nlm.nih.gov/pubmed/36328377)Choueiri T, Kluger H, George S, Tykodi S, Procopio M, Castonguay V, Folefac E, Lee C, Hotte S, Miller W, Saggi S, Lee C, Desilva H, P, Motzer R, Escudier B. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy Journal For in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance](http://www.ncbi.nlm.nih.gov/pubmed/36313654)Schoenfeld D, Merkin R, Moutafi M, Martinez S, Adeniran Kumar D, Jilaveanu L, Hurwitz M, Rimm D, Kluger H. Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic modify beta cells and cause checkpoint inhibitor-induced diabetes](http://www.ncbi.nlm.nih.gov/pubmed/35925682)Perdigoto AL, Deng S, Du KC, Kuchroo M, Burkhardt DB, Tong A, Israel G, Robert ME, Weisberg SP, Kirkiles-Smith N, Stamatouli AM, Kluger HM, MJ, Pober JS, Anderson MS, Krishnaswamy S, Herold KC. Immune cells and their inflammatory mediators modify beta cells and cause checkpoint A, Bosenberg M, Brastianos P, Cahill DP, Chen Holmen Hernando E. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities Pigment Cell Rioth M, Zhang C, Palaia J, Pisupati R, Bond C, Rosenblatt L, Broome R, Teka M, Kluger H. 1582P Real-world management of immune-related adverse events in Of Oncology 2022, 33: s1268-s1269. [DOI: investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody](https://doi.org/10.1016/j.annonc.2022.07.970)Larkin J, Dalle S, Sanmamed M, Wilson M, Hassel J, Kluger H, Orloff M, Weber J, Finckenstein F, Hari P, Jagasia M, Yin H, Shi W, Sulur G, Wu X, Gontcharova V, Lewis K. 844P Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer](http://www.ncbi.nlm.nih.gov/pubmed/35902131)Silk AW, Barker CA, Bhatia S, EA, MT, Brownell I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer Journal SOX2 as a critical regulator of metastatic outgrowth in melanoma Cellular And Molecular and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US](http://www.ncbi.nlm.nih.gov/pubmed/35771575)Ermer T, Canavan ME, Maduka RC, Li AX, Salazar MD, Zhan PL, Mase V, Kluger H, Boffa DJ. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US JAMA (TIL) cell therapy.](https://doi.org/10.1200/jco.2022.40.16_suppl.9524)Kluger H, Sarnaik A, Chesney J, Lewis K, Weber J, Gogas H, In G, Terheyden P, Lee S, Jagasia M, Masteller E, Qi R, Gontcharova V, Shi W, Fiaz R, Sulur G, Wu R, Chen G, Thomas S. Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-na\u00efve and melanoma treated with lifileucel, a tumor-infiltrating [DOI: A, C, Etts K, Kluger H, Sznol M. Clinical predictors of with 9555-9555. interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy](http://www.ncbi.nlm.nih.gov/pubmed/35354588)Baker ML, Yamamoto Y, Perazella MA, Dizman N, FP, Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy J, Hodi FS. Reply to T. Olivier et al Mahajan A, Etts K, Zhang L, Aizenbud L, Perdigoto AL, Hurwitz M, Sznol M, Herold KC, Kluger HM. Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss Qu R, Kluger Y, Chen TM, Hollander L, Safirstein R, Nelson B, Cha C, Bosenberg drives tumour rejection by promoting T cell activation European Daud AI, Hafler DA, Kluger HM, Raychaudhuri S, Sharpe AH. TCR-sequencing in cancer and a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review](http://www.ncbi.nlm.nih.gov/pubmed/35047671)Heng JS, Kim JM, Jones DK, Stoessel KM, Weiss SA, Sznol M, Kluger HM, Walter SD, Silverstein NA, Pointdujour-Lim R. Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series H. CheckMate-067: Raising the Bar for the Next Decade in Oncology Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally.](http://www.ncbi.nlm.nih.gov/pubmed/34564774)Esposito A, Jacobs D, Ariyan S, Galan A, Kluger H, Clune J, Weiss S, Tran T, Olino K. ASO Visual Abstract: Merkel Cell Carcinoma-Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally. Annals Of combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy](https://doi.org/10.1136/jitc-2021-sitc2021.389)Weiss S, Sznol M, Shaheen M, Berciano-Guerrero R, Berrocal A, E, Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy Of PK. cell immune contexture in lung cancer-associated brain metastases](http://www.ncbi.nlm.nih.gov/pubmed/34670827)Lu BY, Gupta R, Aguirre-Ducler Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases Song E, Blenman KRM, Micevic Yan Q. KDM5B promotes immune evasion Solid Tumors](https://doi.org/10.1016/j.jtho.2021.08.335)Gettinger Kluger H, Schoenfeld A, Warner A, He K, Sukari A, Thomas S, Doger B, Lee S, Haefliger S, Goldberg Z, Cacovean A, Fiaz R, Chen G, Jagasia M, Finckenstein F, Fardis M, Jimeno A. P14.05 Lymphocytes (Lifileucel, LN-144, LN-145, Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally](https://doi.org/10.1245/s10434-021-10784-7)Esposito A, Jacobs D, Ariyan S, Galan A, Kluger H, Clune J, Weiss S, Tran T, Olino K. ASO Visual Abstract: Merkel Cell Carcinoma\u2014Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally Annals Of Surgical Oncology 2021, 28: 736-737. [DOI: 10.1245/s10434-021-10784-7](https://doi.org/10.1245/s10434-021-10784-7). Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally](http://www.ncbi.nlm.nih.gov/pubmed/34494169)Esposito A, Jacobs D, Ariyan S, Galan A, Kluger H, Clune J, Weiss S, Tran T, Olino K. Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally Annals Of Have Minimal Impact on Prognosis.](http://www.ncbi.nlm.nih.gov/pubmed/34424955)Yang C, Shuch B, Kluger HM, Serrano M, Kibel AS, Humphrey PA, Adeniran AJ. Adverse Histopathologic Characteristics in Small Papillary Renal Cell Carcinomas Have Minimal Impact on Prognosis. American Journal Of intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis](http://www.ncbi.nlm.nih.gov/pubmed/34403041)Sandhu MRS, Chiang VL, Tran T, Yu JB, Weiss SA, SB, Aboian MS, Kluger HM, Mahajan A. Correction to: Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis lesions in stage III and IV melanoma: a single institute retrospective analysis](http://www.ncbi.nlm.nih.gov/pubmed/34351544)Sandhu MRS, Chiang VL, Tran T, Yu JB, Weiss S, Goldberg S, Aboian M, Kluger HM, Mahajan A. Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis Renal Cell Carcinoma Patients With Brain Metastases](http://www.ncbi.nlm.nih.gov/pubmed/34432667)Uezono H, Nam D, Kluger HM, Sznol M, Hurwitz M, Yu JB, Chiang VL. Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases American and survival in patients with metastatic non-small cell lung cancer treated with durvalumab and tremelimumab](https://doi.org/10.1158/1538-7445.am2021-489)Dey A, Austin M, Kluger H, Trunova N, Mann H, Shire N, Zhou D, Mugundu G. Abstract 489: Association between immune-mediated adverse events and survival in patients with metastatic non-small cell lung cancer treated with in patients with advanced (unresectable or metastatic) melanoma: durable duration of response at 28 month follow up](https://doi.org/10.1158/1538-7445.am2021-ct008)Chesney J, Larkin J, Kirkwood J, Weber J, Khushalani N, Lewis K, Medina T, Kluger H, Thomas S, Domingo-Musibay E, Ol\u00e1h J, Whitman E, Martin-Algarra S, Corrie P, Lutzky J, Hamid O, Shi W, Wu X, Jagasia M, Finckenstein F, Fardis cryopreserved autologous tumor infiltrating lymphocyte in patients with advanced (unresectable or metastatic) melanoma: durable duration of response at 28 month follow Cancer Research 2021, 81: ct008-ct008. [DOI: 10.1158/1538-7445.am2021-ct008](https://doi.org/10.1158/1538-7445.am2021-ct008). antigen specificity of peripherally derived T cells that infiltrate into solid tumors in patients treated with an autologous T cell therapy, PRIME IL-15 (RPTR-147)](https://doi.org/10.1158/1538-7445.am2021-lb027)Pajerowski J, Gordon W, Bardwell P, McInnis C, Hwang J, Huseni T, Agnihotri P, Francis J, Tarr C, Renoux F, Heer S, Cerreghetti-Terraneo N, Loi M, Hamilton E, Nikiforow S, Blumenschein G, Christea M, Osman K, Shields A, Kluger H, Obermair F, Pregibon D, Kisielow J, Coyle A, Skoberne M. Abstract LB027: Tracking and decoding the antigen specificity of peripherally derived T cells that infiltrate into solid tumors in patients treated with an autologous T cell therapy, PRIME Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1](http://www.ncbi.nlm.nih.gov/pubmed/34140403)Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Levit NS, Anderson G, Zelterman D, Wei W, Mahajan A, Trifan S, Sznol M, Hurwitz M, Kluger HM. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to NA, Green BF, Cottrell TR, Stein JE, Engle EL, Xu H, Ogurtsova A, Roberts C, Wang D, Nguyen P, Zhu Q, Soto-Diaz S, Loyola J, Sander IB, Wong PF, D, Wilton Roskes Eminizer M, Park S, JC, EM, Baras A, De Marzo AM, Topalian JM. Analysis of multispectral imaging with the AstroPath platform informs efficacy of transcriptomic with spatial protein information exceed the predictive value for either single modality](http://www.ncbi.nlm.nih.gov/pubmed/34050252)Vathiotis IA, Yang Z, Reeves J, Toki M, Aung TN, Wong PF, Kluger H, Syrigos KN, Warren S, Rimm DL. Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality Npj (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.](https://doi.org/10.1200/jco.2021.39.15_suppl.9505)Larkin J, Sarnaik A, Chesney J, Khushalani N, Kirkwood J, Weber J, Lewis K, Medina T, Kluger H, Thomas S, Domingo-Musibay E, Olah J, Whitman E, Martin-Algarra S, Corrie P, Lutzky J, Shi W, Wu R, Fardis M, Hamid O. Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy. with autoimmune disorders and advanced malignancies (AIM-NIVO).](https://doi.org/10.1200/jco.2021.39.15_suppl.tps2676)Dumbrava E, Dougan M, Gupta S, Cappelli L, Katsumoto T, Rahma O, Painter J, Wang Y, Suarez-Almazor M, Reid P, Wesley S, Hafler D, Bingham C, Warner B, Chung L, Ott P, Kluger H, Khosroshahi A, Tawbi H, Sharon E. A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick Whitman S, JMG, Shi W, Takamura T, Jagasia M, Qin H, Wu Chartier immunosuppressants and association with outcome: E1609 study analysis](http://www.ncbi.nlm.nih.gov/pubmed/33963015)Tarhini AA, Kang N, Lee Cohen GI, Hamid O, TM, Streicher H, Sondak adjuvant use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 CD8+ T cells and patient survival in cutaneous melanoma](http://www.ncbi.nlm.nih.gov/pubmed/33962358)Zhu G, Su H, Johnson CH, Khan SA, Kluger H, Lu L. Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/33879601)Nghiem P, Bhatia Sharfman Reddy SA, Boulmay BC, Riker A, Burgess MA, Hanks BA, Olencki T, Kendra K, Church C, Akaike T, Ramchurren N, Shinohara MM, Salim B, Taube JM, Jensen E, Kalabis M, Fling SP, Moreno B, Sharon E, Cheever MA, Topalian SL. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma Journal lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumours](https://doi.org/10.1016/s1556-0864(21)02029-3)Gettinger S, Kluger H, Schoenfeld A, Warner A, He K, Sukari A, Thomas S, de Sp\u00e9ville B, Lee S, Haefliger S, Goldberg Z, Cacovean A, Fiaz R, Chen G, Jagasia M, Finckenstein F, Fardis M, Jimeno A. 187TiP Phase of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) Jessel S, Zhang L, Raddassi K, Zhang L, Olino K, Clune J, Singer M, Kluger HM, Hafler DA. Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells Journal Of Tumor-Associated CK, Zito CR, in Melanoma by Subcellular Herold KC. Adverse events induced by immune checkpoint inhibitors Current tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity](http://www.ncbi.nlm.nih.gov/pubmed/33606757)Higgins AY, Arbune A, Soufer A, Ragheb E, Kwan JM, Lamy J, Henry M, Cuomo JR, Charifa A, Gallegos C, Hull S, Coviello JS, Bader AS, Peters DC, Huber S, Mojibian HR, Sinusas AJ, Kluger H, Baldassarre LA. Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor prognostic value to standard assessment of depth and ulceration in primary melanoma](http://www.ncbi.nlm.nih.gov/pubmed/33531581)Moore MR, Friesner ID, Rizk EM, Fullerton Mondal M, Trager MH, Mendelson K, Chikeka I, Kurc T, Gupta R, Rohr BR, Robinson EJ, Acs B, Chang R, Kluger H, Taback B, Messina J, Ferringer J, Wang J, Vanguri R, Saenger YM. Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in with Imaging Mass CytometryMultiplex Discovery with Imaging Mass Cytometry](http://www.ncbi.nlm.nih.gov/pubmed/33504554)Martinez-Morilla S, Villarroel-Espindola F, Wong Toki Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass CytometryMultiplex Discovery with Imaging for Immune Checkpoint Inhibitor Induced Acute Kidney Injury in a Patient with Concurrent Immunotherapy-Associated Diabetes: A Case Report.](http://www.ncbi.nlm.nih.gov/pubmed/33763663)Jessel S, Austin M, Kluger HM. Mycophenolate as Primary Treatment for Immune Checkpoint Inhibitor Induced Acute Kidney Injury in a Patient with Concurrent Immunotherapy-Associated Diabetes: A Case Report. Clinical [PMID: 33763663](https://pubmed.ncbi.nlm.nih.gov/33763663), [PMCID: PMC7985664](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985664). [Prolonged Complete Response of Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy.](http://www.ncbi.nlm.nih.gov/pubmed/34382032)Unlu S, Grant MJ, Gettinger S, Adeniran A, Kluger HM. Prolonged Complete Response of Early Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy. S, Goldberg SB, Kluger HM, Nguyen D, Patel A, Chiang V. Tumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States](http://www.ncbi.nlm.nih.gov/pubmed/33146688)Jacobs D, Huang H, Olino K, Weiss S, Kluger H, Judson BL, Zhang Y. Assessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United in metastatic melanoma and association with outcome on immunotherapy](http://www.ncbi.nlm.nih.gov/pubmed/33457084)Martinez-Morilla S, Zugazagoitia J, Wong PF, Kluger HM, Rimm DL. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients](https://doi.org/10.1136/jitc-2020-sitc2020.0801)Hamilton E, Nikiforow S, Bardwell P, McInnis C, Zhang J, Blumenschein G, Cristea M, Osman K, Shields A, Motta M, Bilic S, Schoenborn-Kellenberger O, Rakestraw J, Carey S, Geretti E, Sauer K, Harris T, Maniar T, Hewes B, T, Fitzgerald J, Kluger H. 801 PRIME IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients Journal For ImmunoTherapy Of Cancer 2020, 8: a850-a850. [DOI: 10.1136/jitc-2020-sitc2020.0801](https://doi.org/10.1136/jitc-2020-sitc2020.0801). - Jacobs Olino S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck 164: 1214-1221. H, Baldassarre LA. Cardiac Biventricular compared to matched extracranial metastases](http://www.ncbi.nlm.nih.gov/pubmed/32974852)Weiss SA, Zito C, Tran T, Heishima brain metastases have and density compared to Kluger H. Targeting Innate Immunity to Treat Cancer Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors.](http://www.ncbi.nlm.nih.gov/pubmed/33778814)Perdigoto AL, Tran T, Patel N, Clark P, Patell K, Stamatouli AM, Reddy V, Clune J, Herold KC, Robert ME, Kluger HM. Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors. Clinical Oncology, Case Reports 2020, 3 [PMID: 33778814](https://pubmed.ncbi.nlm.nih.gov/33778814), [PMCID: PMC7993656](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993656). [Abstract 3095: Combination of spatial protein data with bulk transcriptional profiling of the same cohort shows relationships between RNA and protein and facilitates combined predictive signatures](https://doi.org/10.1158/1538-7445.am2020-3095)Vathiotis I, Reeves J, Toki M, Wong P, Kluger H, Aung T, Syrigos K, Warren S, Rimm D. Abstract 3095: Combination of spatial protein data with bulk transcriptional profiling of the same cohort shows relationships between RNA and protein and facilitates combined predictive signatures Cancer Research 2020, 80: cytometry](https://doi.org/10.1158/1538-7445.am2020-2001)Martinez-Morilla S, Villarroel-Espindola F, Wong P, Kluger H, Toki M, Aung T, Pelekanou V, Bourke-Martin D. Abstract 2001: Biomarker discovery in immunotherapy-treated melanoma patients phase 1b study patients with autoimmune disorders and advanced malignancies (AIM-NIVO)](https://doi.org/10.1158/1538-7445.am2020-ct249)Ileana Dumbrava E, Suarez-Almazor M, Painter J, Johanns T, Dougan M, Cappelli L, Wang Y, Bingham C, Gupta S, Warner B, Rahma O, Naidoo J, Ott P, Hafler D, Kluger H, Khosroshahi A, Naqash R, Chung L, Katsumoto T, Kummar S, Tawbi H, Sharon E. Abstract CT249: A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO) Cancer Research 2020, 80: Idoate MA, Lu B, J, RS, Gil-Bazo I. PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Cancer 2020, 26: 4186-4197. [PMID: 32354698](https://pubmed.ncbi.nlm.nih.gov/32354698), [DOI: 10.1158/1078-0432.ccr-20-0798](https://doi.org/10.1158/1078-0432.ccr-20-0798). - Oria Zhu H, Deng G, Zito C, Rane C, Zhang S, Weiss S, Tran T, Adeniran A, Zhang F, Zhou J, Kluger Y, Bosenberg M, Kluger H, Jilaveanu L. 19. PLEKHA5 REGULATES TUMOR Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)](http://www.ncbi.nlm.nih.gov/pubmed/32439653)Diab A, Tannir NM, Bentebibel U, Aung S, Fanton C, Rizwan A, Iacucci E, Liao Y, Bernatchez C, Hurwitz ME, Cho DC. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02) Cancer 2020, JM, Farhadian S, Kluger HM, Kluger Y. Impact of healthcare worker shift scheduling on workforce preservation during the COVID-19 pandemic Infection Control And Hospital Epidemiology 2020, 41: 1443-1445. Metastases: Melanoma infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.](https://doi.org/10.1200/jco.2020.38.15_suppl.10006)Sarnaik A, Khushalani N, Chesney J, Lewis K, Medina T, Kluger H, Thomas S, Domingo Musibay E, Pavlick A, Whitman E, Martin-Algarra S, Corrie P, Lutzky J, Hamid O, Wu R, Shi W, Fardis M, Weber J, Larkin J, Kirkwood J. Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies. Journal Of Clinical Oncology study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.](https://doi.org/10.1200/jco.2020.38.15_suppl.3094)Shapira R, Weber J, Geva R, Sznol M, Kluger H, Wong D, Liang B. A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies. Journal Of Clinical Oncology 2020, treatment-refractory advanced renal cell carcinoma (aRCC).](https://doi.org/10.1200/jco.2020.38.15_suppl.5007)Choueiri T, Kluger H, George S, Tykodi S, Kuzel S, Procopio M, Castonguay V, Folefac E, Lee C, Hotte S, Miller W, Saggi S, Gold D, Motzer R, Escudier B. FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma phase Ib study autoimmune disorders and advanced malignancies (AIM-NIVO).](https://doi.org/10.1200/jco.2020.38.15_suppl.tps3158)Ileana Dumbrava E, Suarez-Almazor M, Painter J, Johanns T, Dougan M, Cappelli L, Bingham C, Wang Y, Gupta S, Warner B, Rahma O, Naidoo J, Ott P, Hafler D, Kluger H, Khosroshahi A, Katsumoto T, Kummar S, Sharon E, Tawbi H. A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). anti-programmed cell death locally advanced basal cell carcinoma in treatment-naive patients: A case series](http://www.ncbi.nlm.nih.gov/pubmed/32613057)Ligtenberg KG, Hu JK, Damsky K, Kluger H, Clune J, Cowper SE, Panse G, Leventhal J, Weiss SA. Neoadjuvant anti-programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case Vaisman A, Abu Ahmad Y, Zohar Y, Zhang T, Lee JS, Lazar I, Sheikh Khalil S, Feiler Y, Kluger C, Brown K, Ruppin of eIF2 by RNF4 Promotes Melanoma Tumorigenesis and Therapy infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies - independent review committee data update](https://doi.org/10.1136/lba2019.18)Sarnaik A, Khushalani N, Chesney J, Kluger H, Curti B, Lewis K, Medina T, Thomas S, Pavlick A, Whitman E, Algarra S, Corrie P, Hamid O, Lutzky J, Olah J, Weber J, Larkin J, Shi W, DiTrapani K, Qin H, Mirgoli M, Wu R, Takamura T, Fardis M, Kirkwood J. P865 Safety & efficacy lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies - independent review committee data update Journal For ImmunoTherapy Of Cancer 2020, 8: a12. [DOI: 10.1136/lba2019.18](https://doi.org/10.1136/lba2019.18). [Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 Clune J, Ariyan S, Cha C, Weiss SA, Kluger HM, Sznol M. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce](http://www.ncbi.nlm.nih.gov/pubmed/32238470)Kluger HM, Tawbi HA, Ascierto ML, MK, CG, Gulley TM, Le DT, Hubbard-Lucey VM, Papadimitrakopoulou VA, Postow Rubin EH, Sharon E, JM, Topalian SL, Zappasodi R, Sznol M, Sullivan RJ. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce Journal Architecture, Rather Than Typing of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis](http://www.ncbi.nlm.nih.gov/pubmed/32101890)Yang C, Shuch B, Kluger H, Humphrey PA, Adeniran AJ. High WHO/ISUP Grade and Unfavorable Architecture, Rather Than Typing of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis The American Journal Of Surgical Pathology 2020, 44: 582-593. [PMID: 32101890](https://pubmed.ncbi.nlm.nih.gov/32101890), Tawbi H. Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy 2020, 1421-1454. [DOI: 10.1007/978-3-030-05070-2_65](https://doi.org/10.1007/978-3-030-05070-2_65). [Leptomeningeal disease in melanoma patients: An and future directions](http://www.ncbi.nlm.nih.gov/pubmed/31916400)Glitza IC, Smalley KSM, Brastianos PK, Davies MA, McCutcheon Arrington JA, Evernden BR, Smalley I, Eroglu Z, Khushalani N, Margolin MB, A, Forsyth P. Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions Pigment Cell & Melanoma Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis](http://www.ncbi.nlm.nih.gov/pubmed/33147119)Tran TT, Gallezot Zito Huang H, Huttner A, Kluger HM, Chiang VL, Carson R. [11C]Methionine and [11C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis Molecular Plasma Renalase, and Their Association With All-Cause Mortality](http://www.ncbi.nlm.nih.gov/pubmed/32154458)Chang J, Guo X, Rao V, Gromisch ES, Chung S, Kluger HM, Cha C, Gorelick F, Testani J, Safirstein R, Crowley S, Peixoto AJ, Desir GV. Identification of Two Forms of Human Plasma Renalase, and Their Association With All-Cause Mortality Kidney International HM. Complications associated with immunotherapy for Rosenberg AS, Rongioletti F, Pilloni L, D'Hallewin S, Gueorguieva mass [PMID: 31697431](https://pubmed.ncbi.nlm.nih.gov/31697431), 10.1111/cup.13610](https://doi.org/10.1111/cup.13610). Zito CR, Oria VO, Rane CK, Zhang S, Weiss SA, Tran T, Zhang F, Zhou MW, M, Tran T, Jilaveanu L, Cohen J, Hegde U, Wei W, Mahajan A, Goldberg S, Chiang V, Weiss S. RBTT-07. A PHASE 2 TRIAL OF PEMBROLIZUMAB AND BEVACIZUMAB IN H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death](http://www.ncbi.nlm.nih.gov/pubmed/31636101)Kulkarni PM, Robinson EJ, PF, Acs B, Rizk EM, Yang C, Mondal M, Moore MR, Osman I, Phelps R, Horst BA, Chen ZS, Ferringer T, Rimm DL, Wang J, Saenger YM. Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death Clinical Cancer Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab](http://www.ncbi.nlm.nih.gov/pubmed/31358540)Hamid O, Molinero L, Bolen CR, Sosman M, O'Hear C, Chen DS, Hegde PS, Hodi FS. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab patients (pts) with advanced melanoma: Phase III LEAP-003 study](https://doi.org/10.1093/annonc/mdz255.063)Eggermont A, Carlino P, Arance A, Daud A, O'Day S, Taylor M, Smith A, Rodgers A, Moreno B, Diede S, Kluger H. 1375TiP Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study Annals [DOI: 10.1093/annonc/mdz255.063](https://doi.org/10.1093/annonc/mdz255.063). [Closed system RT-qPCR as diagnostic test for immunotherapy outcome in metastatic melanoma](http://www.ncbi.nlm.nih.gov/pubmed/31533832)Gupta S, McCann L, Chan YGY, Lai EW, Wei W, Wong PF, Smithy JW, Weidler J, Rhees B, Bates M, Kluger HM, Rimm DL. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma Journal For Immunotherapy-Treated Patients Using Digital Spatial Profiling](http://www.ncbi.nlm.nih.gov/pubmed/31189645)Toki MI, Merritt CR, PF, Smithy JW, Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling Clinical Measure of the Effects of Immune Checkpoint Inhibition\u2014A Pooled Analysis of Patients With Advanced Melanoma](http://www.ncbi.nlm.nih.gov/pubmed/31498030)Regan MM, Werner L, Rao S, Gupte-Singh K, Hodi MB, McDermott DF. Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition\u2014A Pooled Analysis of Patients With Advanced Melanoma Journal Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With SB, Kluger HM, Chiang VLS. Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors International Journal Of 1113-1118. Nolte A, Ghabili K, Cheng M, Liu S, Chiang V, Kluger H, Hurwitz M, Shuch B. Brain Metastasis From Renal-Cell Carcinoma: An and implications for treatment with immune therapy](http://www.ncbi.nlm.nih.gov/pubmed/31362777)Tran TT, Mahajan A, Chiang VL, HM. Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy Journal For ImmunoTherapy Of Cancer with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma](http://www.ncbi.nlm.nih.gov/pubmed/31340861)Klemen ND, Wang M, Feingold PL, Cooper K, Pavri Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, Clune J, Ariyan S, Salem RR, Weiss SA, Kluger HM, Sznol M, Cha C. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma Journal melanoma](http://www.ncbi.nlm.nih.gov/pubmed/31337426)Wong JW, Zelterman HM, Rimm DL. Multiplex immunotherapy outcome in metastatic melanoma transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasis](https://doi.org/10.1158/1538-7445.sabcs18-4552)Wingrove E, Liu Z, Nguyen D, Arnal-Estape A, Patel K, Melnick M, Politi K, Valiente M, Kluger H, Chiang V. Abstract 4552: BMX-Seq as a new resource for deciphering the transcriptomic hallmarks of tumor plasticity transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasis](https://doi.org/10.1158/1538-7445.am2019-4552)Wingrove E, Liu Z, Nguyen D, Arnal-Estape A, Patel K, Melnick M, Politi K, Valiente M, Kluger H, Chiang V. Abstract 4552: BMX-Seq as a new resource for deciphering the transcriptomic hallmarks of tumor plasticity and stromal in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC)](https://doi.org/10.1158/1538-7445.sabcs18-ct089)Kluger H, Weiss S, Olszanski A, Schuchter L, Linette G, Garland L, Iannotti N, Johnson M, Avsar E, Srivastava M, Trifan O, Edelman M. Abstract CT089: Phase Ib/II CD40 agonistic antibody APX005M in subjects with metastatic melanoma (M) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC)](https://doi.org/10.1158/1538-7445.am2019-ct089)Kluger H, Weiss S, Olszanski A, Schuchter L, Linette G, Garland L, Iannotti N, Johnson M, Avsar E, Srivastava M, Trifan O, Edelman M. Abstract CT089: Phase Ib/II CD40 agonistic antibody APX005M in subjects with metastatic melanoma (M) or non-small panel and immunotherapy outcome in metastatic melanoma](https://doi.org/10.1158/1538-7445.sabcs18-3142)Gupta S, McCann L, Chan Y, Lai E, Wong P, Smithy J, Weidler J, Rhees B, Bates M, CD274, in panel and immunotherapy outcome in metastatic melanoma](https://doi.org/10.1158/1538-7445.am2019-3142)Gupta S, McCann L, Chan Y, Lai E, Wong P, Smithy J, Weidler J, Rhees B, Bates M, CD274, in panel and immunotherapy metastatic 10.1158/1538-7445.am2019-3142](https://doi.org/10.1158/1538-7445.am2019-3142). Jilaveanu L, Turner Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors Journal For ImmunoTherapy Novel IL2R-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors](http://www.ncbi.nlm.nih.gov/pubmed/30988166)Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker M, Biomarker Analysis of NKTR-214, a Novel IL2R-Biased Cytokine, in Patients with Advanced or Metastatic Solid nivolumab.](https://doi.org/10.1200/jco.2019.37.15_suppl.2623)Hurwitz M, Cho D, Balar M, Kluger H, Bernatchez C, Fanton C, Iacucci E, Liu Y, Nguyen T, Overwijk W, Zalevsky J, Tagliaferri M, Hoch U, Diab A. Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and Of Clinical Damsky W, Kluger H, Bosenberg M. Evaluating the role of the COX2/PGE2 pathway in anti-melanoma immunity. Journal Of Clinical Oncology 2019, 37: e14114-e14114. [DOI: 10.1200/jco.2019.37.15_suppl.e14114](https://doi.org/10.1200/jco.2019.37.15_suppl.e14114). [Functional profile and clinical of tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases.](https://doi.org/10.1200/jco.2019.37.15_suppl.2066)Lu B, Gupta R, Stewart T, Kluger H, Jilaveanu L, Schalper K, Goldberg S. Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.](https://doi.org/10.1200/jco.2019.37.15_suppl.2518)Sarnaik A, Khushalani N, Chesney J, Kluger H, Curti B, Lewis K, Thomas S, Whitman E, Hamid O, Lutzky J, Pavlick A, Weber J, Larkin J, Barton D, Yung L, Suzuki S, Fardis M, Kirkwood J. Safety and efficacy of cryopreserved autologous infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1. Journal Of Clinical Oncology 2019, 37: 2518-2518. States phase randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-2b for resected high-risk melanoma.](https://doi.org/10.1200/jco.2019.37.15_suppl.9504)Tarhini A, Lee S, Hodi F, Rao U, Cohen G, Hamid O, Hutchins L, Sosman J, Kluger H, Sondak V, Koon H, Lawrence D, Kendra K, Minor D, Lee C, Albertini M, Flaherty L, Petrella T, Kirkwood J. United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-2b for combined nivolumab (NIVO) and ipilimumab (IPI) in with J, Wolchok J, Callahan M, Kluger H, Postow M, Segal N, Lesokhin A, Balogh A, Re S, Sznol M. Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with with advanced melanoma previously exposed to anti-PD-1/PD-L1 agents: Phase 2 LEAP-004 Daud A, Eggermont A, Hauschild A, Kluger H, Taylor M, Smith A, Chen K, Krepler C, Diede S, O'Day S. Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma previously exposed to anti-PD-1/PD-L1 agents: Phase 2 LEAP-004 tps9594-tps9594. Tawbi H. Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy 2019, 1-34. [DOI: 10.1007/978-3-319-46029-1_65-1](https://doi.org/10.1007/978-3-319-46029-1_65-1). [Multiplex Quantitative Melanoma](http://www.ncbi.nlm.nih.gov/pubmed/30617133)Wong K, Zelterman D, HM, Lymphocytes and Immunotherapy Zhu L, Kluger HM, Chiang VL, Nguyen DX. Transcriptomic Hallmarks of Tumor Plasticity and Stromal ArnalEstape A, Melnick M, Politi K, Monteiro C, Zhu L, Valiente M, Kluger H, Chiang V, Nguyen D. Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.](https://doi.org/10.1200/jco.2019.37.8_suppl.136)Sarnaik A, Thomas S, Davar D, Kirkwood J, Kluger H, Lutzky J, Wilson M, Pavlick A, Curti B, Whitman E, Phan G, Ernstoff M, Takamura K, Barton D, Suzuki S, Karyampudi L, Samberg N, Fardis M, Chesney J. Safety and of cryopreserved autologous infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy. Journal Of Clinical Oncology 2019, 37: 136-136. [DOI: 10.1200/jco.2019.37.8_suppl.136](https://doi.org/10.1200/jco.2019.37.8_suppl.136). GV, Tawbi HA, Goldberg SB, Chiang VL. Reply to A. Shinde et al Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley Forsyth PA, Davies MA, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities Pigment Cell & Melanoma Kluger H, Weiss S, Chow J, Stoessel K, Kombo N, Del Priore L, Pointdujour-Lim R. Ophthalmic Adverse and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy](http://www.ncbi.nlm.nih.gov/pubmed/30726175)Nghiem P, Bhatia Reddy SA, Boulmay BC, Riker AI, T, Margolin K, Lundgren LM, Soni A, Ramchurren SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Moreno B, Sharon E, Cheever MA, Topalian SL. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy Journal patients with Merkel cell carcinoma receiving anti-PD-1 therapy](http://www.ncbi.nlm.nih.gov/pubmed/30482247)Miller NJ, Church CD, Fling SP, Kulikauskas R, Ramchurren Shinohara MM, Kluger S, Lundgren L, Cheever MA, Topalian SL, Nghiem P. Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy Journal For ImmunoTherapy Of With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial](http://www.ncbi.nlm.nih.gov/pubmed/30407895)Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, Perrotti E, Anderson G, Ralabate A, Kluger Y, Wei W, Goldberg SB, Jilaveanu LB. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial Journal A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management](http://www.ncbi.nlm.nih.gov/pubmed/30399387)Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management Journal Of The American Academy Of Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma](https://doi.org/10.1016/j.ijrobp.2018.06.134)Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma International Journal Oncology Biology Physics 2018, 102: [DOI: 10.1016/j.ijrobp.2018.06.134](https://doi.org/10.1016/j.ijrobp.2018.06.134). [Results Phase II Trial of Cabozantinib in Patients with Non-small-cell Carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/30528315)Hellerstedt BA, Vogelzang NJ, Kluger HM, Yasenchak CA, Aftab DT, Ramies DA, Gordon MS, Lara P. Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma Clinical Lung 20: 74-81.e1. Syed J, Nguyen KA, McGillivray P, Adeniran A, Humphrey P, Dancik GM, Kluger Y, Liu Z, Kluger H, Shuch B. Genomic Heterogeneity and the Small Renal K, 3638: tumor-infiltrating lymphocytes and by NanoString Digital Spatial Profiling technology and quantitative immunofluorescence](https://doi.org/10.1158/1538-7445.am2018-3621)Toki M, Wong P, Kluger H, Liu Y, Merritt C, Ong G, Warren S, Beechem J, Rimm D. Abstract 3621: High-plex immune marker spatial profiling quantitation by NanoString Digital Spatial Profiling technology and quantitative Research 2018, 78: 3621-3621. [DOI: 10.1158/1538-7445.am2018-3621](https://doi.org/10.1158/1538-7445.am2018-3621). [Abstract CT169: A phase II, multicenter study to assess the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-144) for treatment of patients with metastatic melanoma](https://doi.org/10.1158/1538-7445.am2018-ct169)Sarnaik A, Curti B, Davar D, Hamid O, Lutzky J, Wilson M, Kluger H, Chesney J, Kim K, Phan G, Thomas S, Whitman E, Larsen B, Suzuki S, Samberg N, Gorbatchevsky I, Fardis M, Kirkwood J. Abstract CT169: A phase II, multicenter study to assess the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-144) for treatment of patients Quandt PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. Collateral Damage: Insulin-Dependent Diabetes Induced With and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.](https://doi.org/10.1200/jco.2018.36.15_suppl.2009)Goldberg S, Gettinger S, Mahajan A, Herbst Chiang R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W, Chiang V, Kluger H. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. Oncology 2018, 36: 2009-2009. [DOI: 10.1200/jco.2018.36.15_suppl.2009](https://doi.org/10.1200/jco.2018.36.15_suppl.2009). [Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with non-small lung cancer (NSCLC) or melanoma.](https://doi.org/10.1200/jco.2018.36.15_suppl.9099)Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) edema and blood vessel characteristics in brain metastases and implications for treatment with immune therapy.](https://doi.org/10.1200/jco.2018.36.15_suppl.9572)Tran T, Jilaveanu L, Mahajan A, Goldberg S, Nguyen D, Chiang V, Kluger H. Perilesional edema and blood vessel characteristics in brain metastases and implications for treatment with immune therapy. Journal Of Oncology advanced solid tumors: Preliminary phase 1/2 results of PIVOT.](https://doi.org/10.1200/jco.2018.36.15_suppl.3006)Diab A, Hurwitz M, Cho D, Papadimitrakopoulou V, Curti B, Tykodi S, Puzanov I, Ibrahim N, Tolaney S, Tripathy D, Gao J, Siefker-Radtke A, Clemens W, Tagliaferri M, Gettinger S, Kluger H, N. NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT. Journal Of Clinical Oncology 2018, 36: 3006-3006. [DOI: 10.1200/jco.2018.36.15_suppl.3006](https://doi.org/10.1200/jco.2018.36.15_suppl.3006). [Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy.](https://doi.org/10.1200/jco.2018.36.15_suppl.9506)Nghiem P, Bhatia S, Lipson Sharfman Kudchadkar Friedlander P, Brohl A, Daud A, Kluger H, Reddy S, Burgess M, Hanks B, Olencki T, Boulmay B, Lundgren L, Ramchurren N, Homet Moreno B, Sharon E, Cheever M, Topalian S. Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy. Journal Of Clinical Oncology 2018, 36: 9506-9506. [DOI: 10.1200/jco.2018.36.15_suppl.9506](https://doi.org/10.1200/jco.2018.36.15_suppl.9506). - Lu B, Gupta R, Ribeiro M, Stewart T, Chiang V, Contessa J, Adeniran A, Kluger H, Jilaveanu L, Schalper K, Goldberg S. PD-L1 expression and tumor-infiltrating lymphocytes in lung cancer brain 36: e24116-e24116. [DOI: 10.1200/jco.2018.36.15_suppl.e24116](https://doi.org/10.1200/jco.2018.36.15_suppl.e24116). [A phase 2, multicenter efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of melanoma.](https://doi.org/10.1200/jco.2018.36.15_suppl.tps9595)Sarnaik A, Curti B, Davar D, Kirkwood J, Hamid O, Lutzky J, Wilson M, Kluger H, Whitman E, Phan G, Thomas S, Lewis K, Arkenau H, Chesney J, Larsen B, Gorbatchevsky I, Suzuki S, Samberg N, Fardis M. A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients Clinical Sznol M, Schalper K, \"Kevin\" Kim H. Safety and feasibility of immuno-cryotherapy. Journal Of Clinical Oncology 2018, 36: 34-34. [DOI: 10.1200/jco.2018.36.5_suppl.34](https://doi.org/10.1200/jco.2018.36.5_suppl.34). - Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, Bacchiocchi A, Kluger H, Wei W, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM. Early B cell changes predict autoimmunity following combination immune checkpoint blockade Journal Of Clinical 128: K, J, Asmellash SG, Roder J, Roder H. A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805](http://www.ncbi.nlm.nih.gov/pubmed/29066509)Jilaveanu LB, Puligandla M, Weiss SA, Wang X, KT, Boeke M, Neumeister V, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas N, Kluger HM. Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805 Clinical H, Klymenko O, Kim H, Feng Y, Zhang T, Han JY, Murao A, Snipas SJ, Jilaveanu L, Brown K, Kluger H, Zhang H, Iwai K, Ronai Z. SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study](http://www.ncbi.nlm.nih.gov/pubmed/29040030)Callahan MK, Kluger H, Postow Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study Journal O'Day S, Hodi FS, Pavlick AC, Kluger H, Oxborough A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS. Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United and resistance to immunotherapy in cancer patients.](http://www.ncbi.nlm.nih.gov/pubmed/32120553)Weber JS, Woods D, Laino Roder H, Roder J, Blackmon K, Sullivan R. Proteomic and T cell biomarkers identify sensitivity and resistance to immunotherapy in cancer patients. Annals Of Oncology : Official Journal Of The European Society For Medical of anti-CTLA-4 treatment is associated with improved intracranial control](http://www.ncbi.nlm.nih.gov/pubmed/28916225)An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu Wang Mahajan A, Welsh JB, MA, Hwu P, EP, Brown early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors](http://www.ncbi.nlm.nih.gov/pubmed/28223273)Kluger HM, Zito CR, Turcu G, Baine M, Zhang H, Adeniran A, Sznol M, Y, Chen L, Cohen JV, Jilaveanu LB. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors Clinical Cancer response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients](http://www.ncbi.nlm.nih.gov/pubmed/28595336)Sanmamed Fusco Gonzalez Perez G, Alfaro C, Mart\u00edn-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung BRAF and NRAS melanoma](https://doi.org/10.1158/1538-7445.am2017-ct003)Sullivan R, Janku F, Li B, Wong D, Sosman J, Keedy V, Buchbinder E, Tolcher A, Varghese A, Hyman D, Flaherty K, Ribas A, Carvajal R, Wang-Gillam A, Kluger H, Patel M, P, Varterasian M, Welsch D, in on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.](https://doi.org/10.1200/jco.2017.35.15_suppl.2545)Bernatchez C, Haymaker C, Hurwitz M, Kluger H, Tetzlaff M, Jackson N, Gergel I, Tagliaferri M, Zalevsky J, Hoch U, Fanton C, Iacucci E, Aung S, Imperiale M, Liao E, Bentebibel S, Tannir N, Hwu P, Sznol M, Diab A. Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy. Journal Of Clinical Oncology 2017, 35: 2545-2545. [DOI: IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors.](https://doi.org/10.1200/jco.2017.35.15_suppl.e14040)Diab A, Tannir N, Bernatchez C, Haymaker M, Gergel I, Tagliaferri M, Zalevsky J, Hoch U, Aung S, Imperiale M, Cho D, Tykodi S, Puzanov I, Kluger H, Hurwitz M, Hwu P, Sznol M. A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors. Journal Of Clinical Oncology 2017, 10.1200/jco.2017.35.15_suppl.e14040](https://doi.org/10.1200/jco.2017.35.15_suppl.e14040). - Weiss Haas N, Wang X, Zito C, Boeke M, Neumeister V, Manola J, DiPaola R, Kluger H. Microvessel density as a prognostic marker in high-risk renal cell carcinoma. Journal Of Clinical Oncology 2017, 35: anti-PD1 antibody nivolumab H, Callahan M, Weise M, Rawls T, Vitale L, Halim A, Keler T, Davis T, Rizvi N. Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in 2017, heavily pretreated patients with metastatic therapy.](https://doi.org/10.1200/jco.2017.35.15_suppl.3045)Sarnaik Veerapathran A, Simpson-Abelson M, Lotze M, Larsen B, Fischkoff S, Suzuki S, Wang L, Mirgoli M, Fardis M, Curti B. Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.](https://doi.org/10.1200/jco.2017.35.15_suppl.9500)Tarhini A, Lee S, Hodi F, Rao U, Cohen G, Hamid O, Hutchins L, Sosman J, Kluger H, Sondak V, Koon H, Lawrence D, Kendra K, Minor D, Lee C, Albertini M, Flaherty L, Petrella T, Kirkwood J. A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms. Journal Clinical [DOI: [Nuclear IRF-1 expression as a mechanism assess \"Capability\" to express PD-L1 and response to PD-1 therapy in metastatic melanoma](http://www.ncbi.nlm.nih.gov/pubmed/28331615)Smithy JW, Moore LM, Pelekanou PF, Sznol M, Kluger HM, Rimm DL. Nuclear IRF-1 expression as a mechanism to assess \"Capability\" to express PD-L1 and response to PD-1 therapy in metastatic melanoma Journal Goldberg SB, Kluger HM, Chiang VL. Comparing available criteria for measuring brain metastasis response memory phenotype in individual melanoma metastases.](https://doi.org/10.1200/jco.2017.35.7_suppl.3)Dhodapkar K, Boddupalli C, Bar N, Kadaveru K, Krauthammer Pornputtapong N, Mai Z, Ariyan S, Narayan D, Kluger H, Deng Y, Verma R, Das R, Bacchiocchi A, Halaban R, Sznol M, Dhodapkar M. Distinct dominant T-cell receptors with a tissue resident memory phenotype in individual activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma.](https://doi.org/10.1200/jco.2017.35.6_suppl.454)Hurwitz M, Diab A, Bernatchez C, Haymaker C, Kluger H, Tetzlaff M, Gergel U, Zalevsky J, Hwu P, Sznol M, Tannir N. Effect of NKTR-214 on the number and activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma. Journal Of Oncology 2017, 35: 454-454. R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells](http://www.ncbi.nlm.nih.gov/pubmed/28018970)Boddupalli CS, Bar N, Kadaveru K, Krauthammer M, Pornputtapong N, Mai Z, Ariyan S, Narayan D, Kluger H, Deng Y, Verma R, Das R, Bacchiocchi A, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM. Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-Macdonald M. Immunomodulatory Activity of Nivolumab in Metastatic Renal S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM. Melanoma central nervous system metastases: current approaches, challenges, and opportunities Pigment Cell & Kluger HM. Evolving Immunotherapy Approaches for Renal Cell Carcinoma 57. [PMID: 27475806](https://pubmed.ncbi.nlm.nih.gov/27475806), [DOI: 10.1007/s11912-016-0542-9](https://doi.org/10.1007/s11912-016-0542-9). [Abstract combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): across multiple immune pathways without H, Yellin M, Rawls T, Vitale L, Halim A, Davis T, Keler T. Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward [DOI: 10.1158/1538-7445.am2016-ct023](https://doi.org/10.1158/1538-7445.am2016-ct023). [Abstract CT096: Clinical activity, immune and viral correlates of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma](https://doi.org/10.1158/1538-7445.am2016-ct096)Nghiem P, Bhatia S, Lipson E, Kudchadkar R, Miller N, Daud A, Fling K, Olencki T, Reddy S, Shantha E, Sharfman W, Sharon E, Shinohara M, Thompson J, Yearley J, Topalian S, Cheever M. Abstract CT096: Clinical activity, immune and viral correlates of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma Cancer Research 2016, 76: ct096-ct096. [DOI: 10.1158/1538-7445.am2016-ct096](https://doi.org/10.1158/1538-7445.am2016-ct096). [Renalase Expression by Growth through a STAT3-Mediated Mechanism](http://www.ncbi.nlm.nih.gov/pubmed/27197188)Hollander L, Guo X, Velazquez H, Chang J, Safirstein R, Kluger H, Cha C, Desir G. Renalase Expression by Melanoma and Tumor-Associated Macrophages Promotes Tumor Growth through a Shuch B. MET Inhibition in Clear Cell Renal Cell Carcinoma Journal Of checkpoint therapy affect the early radiographic response of melanoma brain metastases JB, Kluger HM, Chiang VL. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain non-small-cell lung cancer and untreated brain metastases: early analysis of non-randomised, open-label, phase Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 AO, Chiang A, Gettinger S, Goldberg S, Kluger HM, Chiang VL. Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases S, Odunsi G, Pandite L, Holdich T, Norry E, Binder-Scholl G, Amado NY-ESO-1 c259 T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing Clinical Oncology 2016, 34: tps3101-tps3101. [DOI: 10.1200/jco.2016.34.15_suppl.tps3101](https://doi.org/10.1200/jco.2016.34.15_suppl.tps3101). [Phase I study and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of (VEGF-A) (sVEGFR2) in plasma](http://www.ncbi.nlm.nih.gov/pubmed/27103123)Li J, Kluger H, Devine L, Lee JJ, Kelly WK, Rink L, Saif MW. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) A, T, Pardoll DM, EM, Sharfman Pembrolizumab in Advanced Merkel-Cell Carcinoma New England 27093365](https://pubmed.ncbi.nlm.nih.gov/27093365), Merino M, Said J, Adeniran A, Nawaf C, Xie Z, Boeke M, Valera B. MP71-12 GENOMIC CHARACTERIZATION OF SARCOMATOID TRANSFORMATION IN CLEAR CELL RENAL CELL CARCINOMA Investigative Urology 2016, 195: e920. [DOI: 10.1016/j.juro.2016.02.1458](https://doi.org/10.1016/j.juro.2016.02.1458). - Cohen JV, Systemic for the Treatment of Brain PMC4881844](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881844), JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi Pantuck AJ, Kluger HM, K, Lifton RP, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma Proceedings Of The National Academy Of Sciences Of The United States Of America Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma](http://www.ncbi.nlm.nih.gov/pubmed/26307133)Wilson MA, Zhao Copy Number Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Kluger H, Xie Z, Nawaf C, Merino M, Valera V, Pantuck A, Said J, A, Lifton R, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Journal Of Clinical Oncology 2016, 34: 509-509. [DOI: 10.1200/jco.2016.34.2_suppl.509](https://doi.org/10.1200/jco.2016.34.2_suppl.509). [Demonstration treated with RS. Demonstration differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery. 29296434](https://pubmed.ncbi.nlm.nih.gov/29296434), [PMCID: PMC5658871](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658871). Lau Feng Fukuda MN, Perlina A, Donn D, Jilaveanu L, ATF2 promotes melanoma Smith Kluger H, Molina AM, Gulati P, A, Ahlers CM, Cardarelli PM, Cohen LJ. necrosis after radiosurgical treatment of brain metastases?](http://www.ncbi.nlm.nih.gov/pubmed/26544782)Colaco RJ, Martin P, Kluger HM, Yu JB, Chiang VL. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors](http://www.ncbi.nlm.nih.gov/pubmed/26448928)Shuch Falbo Adeniran A, Kluger Y, HM, Jilaveanu LB. MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Clinical trials in melanoma patients with brain metastases Pigment Cell A, Evans P, Pornputtapong N, Wu C, McCusker JP, Ma S, Cheng E, Straub R, Serin M, Bosenberg M, Ariyan sequencing in NF1 and metastatic renal cell carcinoma specimens](http://www.ncbi.nlm.nih.gov/pubmed/26317902)Baine MK, Turcu G, Zito Kluger HM, Jilaveanu LB. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell Samples Baine DL, Chen Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable cell carcinoma with emphasis on subtyping](http://www.ncbi.nlm.nih.gov/pubmed/26239624)Alomari AK, Nettey OS, Singh D, Kluger H, Adeniran AJ. Clinicopathological and immunohistochemical characteristics of papillary renal cell carcinoma with emphasis on Human 46: 1418-1426. [PMID: 26239624](https://pubmed.ncbi.nlm.nih.gov/26239624), [DOI: 10.1016/j.humpath.2015.06.006](https://doi.org/10.1016/j.humpath.2015.06.006). - Kluger H, Liu X. At the front line of combating cancer: an interview with Harriet Kluger, MD. The Yale Journal Of Biology And Medicine 2015, 88: 187-9. [PMID: 26029017](https://pubmed.ncbi.nlm.nih.gov/26029017), [PMCID: patients with metastatic non-small cell lung cancer with untreated brain metastases.](https://doi.org/10.1200/jco.2015.33.15_suppl.8035)Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Tsiouris A, Vortmeyer A, Jilaveanu L, Speaker S, Madura M, Rowen E, Gerrish H, Knapp-Perry E, Yao X, Chiang V, Kluger H. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. Journal Clinical Oncology 2015, 33: 8035-8035. J, Vortmeyer A, Jilaveanu L, Ralabate A, Rivera A, Burke M, Hegbe U, Cohen J, Yao X, Speaker S, Madura M, Knapp-Perry E, Mahajan A, Chiang V. Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases. carcinoma (mRCC): Association of biomarkers with clinical outcomes.](https://doi.org/10.1200/jco.2015.33.15_suppl.4500)Choueiri T, Fishman M, Escudier B, McDermott D, Kluger H, Stadler W, Perez-Gracia J, McNeel D, Curti B, Harrison M, Plimack E, Appleman L, Fong L, Drake C, Young T, Chasalow S, Ross-Macdonald P, Simon J, Walker D, Sznol M. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. Journal Of Clinical Oncology 2015, 33: 4500-4500. [DOI: 10.1200/jco.2015.33.15_suppl.4500](https://doi.org/10.1200/jco.2015.33.15_suppl.4500). [Phase 2 vemurafenib in active melanoma brain metastases (coBRIM-B).](https://doi.org/10.1200/jco.2015.33.15_suppl.tps9088)Yee M, Lin Y, Gorantla V, Butterfield Kluger Chapman P, Gangadhar R, Schuchter L, Tarhini A, Kirkwood J, Tawbi H. Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain Biomarker and Potential Mediator of Melanoma Brain and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab](http://www.ncbi.nlm.nih.gov/pubmed/25800770)McDermott DF, Drake A, McDonald D, Sankar V, Sosman JA, Atkins MB. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab Journal Of S, Kluger H, Lupsa B, Herold KC. Precipitation of Autoimmune Diabetes Herzog EL, Lee CG, Peng X, Lee CM, Chen X, Rockwell S, Koo JS, Kluger H, Herbst RS, Sznol M, Elias JA. Role Chitinase 3-like-1 and Semaphorin 7a in Repair JF, Powell SN, Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB KM. Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In M, Kluger H, Choi J. Pregabalin for the treatment of painful hand-foot skin reaction distant sites: A useful marker of primary and metastatic renal cell carcinoma?](http://www.ncbi.nlm.nih.gov/pubmed/25315900)Barr ML, Jilaveanu expression in renal tumours and distant sites: A useful marker of primary and metastatic renal cell carcinoma? Journal Of Clinical melanomas: The Yale University Spitzoid Neoplasm Repository experience, 1991 to 2008](http://www.ncbi.nlm.nih.gov/pubmed/25308882)Lott JP, Wititsuwannakul JJ, Ariyan S, Narayan D, HH, R. with Spitzoid malignant melanomas: The Yale University Spitzoid Neoplasm Repository experience, 1991 to 2008 Journal Of The American Academy Of with BRAF and NRAS mutations and response to treatment with carboplatin, paclitaxel and sorafenib](https://doi.org/10.1158/1538-7445.am2014-933)Wilson M, Zhao F, Khare D'Andrea K, Rimm D, Kirkwood J, Kluger H, Lee S, Schuchter L, Flaherty K, Nathanson K. Abstract 933: Copy number changes are associated with BRAF and NRAS mutations and response to treatment With Advanced Melanoma](http://www.ncbi.nlm.nih.gov/pubmed/25267741)Ott PA, Pavlick AC, Kluger H, Kim KB, Boasberg PD, Simantov R, Crowley E, Green JA, Hawthorne T, Davis TA, Sznol M, Hwu P. Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients Necrosis Following Gamma Knife Radiosurgery in the Treatment of Brain Metastases](https://doi.org/10.1016/j.ijrobp.2014.05.1035)Colaco R, Martin P, Bond J, Bindra R, Contessa J, Kluger H, Yu J, Chiang V. Systemic Treatment and Radiation Necrosis Following Gamma Knife Radiosurgery in the Treatment of Brain Metastases International Journal Of Radiation Oncology Biology Physics 2014, 90: s310. [DOI: 10.1016/j.ijrobp.2014.05.1035](https://doi.org/10.1016/j.ijrobp.2014.05.1035). [Survival, response duration, and nivolumab (NIVO, anti-PD-1, M, Kluger H, Callahan M, Postow M, Gordon R, Segal N, Rizvi N, Lesokhin A, Atkins M, Kirkwood J, Burke M, Ralabate A, Rivera A, Kronenberg S, Agunwamba B, Feely W, Hong Q, Krishnan S, Gupta A, Wolchok J. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, ipilimumab (IPI) HM. NY-ESO-1 as a potential immunotherapeutic target in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib](http://www.ncbi.nlm.nih.gov/pubmed/24714776)Wilson MA, of Somatic Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.](https://doi.org/10.1200/jco.2014.32.15_suppl.4532)Kluger H, Halabi S, Solomon N, Jilaveanu L, Zito C, Sznol J, Nixon A, Rini B, Small E, George D. Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB 10.1200/jco.2014.32.15_suppl.4532](https://doi.org/10.1200/jco.2014.32.15_suppl.4532). activity of nivolumab and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.](https://doi.org/10.1200/jco.2014.32.15_suppl.5012)Choueiri T, Fishman M, Escudier B, Kim J, Kluger H, Stadler W, Perez-Gracia J, McNeel D, Curti B, Harrison M, Plimack E, Appleman L, Fong L, Drake C, Cohen L, Srivastava S, Jure-Kunkel M, Hong Q, Kurland J, Sznol M. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. 2014, 32: 5012-5012. [DOI: 10.1200/jco.2014.32.15_suppl.5012](https://doi.org/10.1200/jco.2014.32.15_suppl.5012). [Long-term survival of (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.](https://doi.org/10.1200/jco.2014.32.15_suppl.9002)Hodi F, Sznol M, Kluger H, McDermott D, Carvajal R, Lawrence D, Topalian S, Atkins M, Powderly J, Sharfman W, Puzanov I, Smith D, Leming P, Lipson E, Taube J, Anders R, Horak C, Kollia G, Gupta A, Sosman J. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I Oncology 2014, 32: 9002-9002. [DOI: 10.1200/jco.2014.32.15_suppl.9002](https://doi.org/10.1200/jco.2014.32.15_suppl.9002). [Survival, response duration, nivolumab (NIVO, anti-PD-1, M, Kluger H, Callahan M, Postow M, Gordon R, Segal N, Rizvi N, Lesokhin A, Atkins M, Kirkwood J, Burke M, Ralabate A, Rivera A, Kronenberg S, Agunwamba B, Feely W, Hong Q, Krishnan S, Gupta A, Wolchok J. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, ipilimumab (IPI) 2014, 32: lba9003-lba9003. [DOI: [Induction of NY-ESO-1 to the Dendritic Cell Receptor DEC-205](http://www.ncbi.nlm.nih.gov/pubmed/24739759)Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, Kluger H, Tejwani J, Ramakrishna V, Crocker A, Vitale L, Yellin M, Davis T, Keler T. Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor 10.1186/1476-4598-13-45](https://doi.org/10.1186/1476-4598-13-45). [Survival, Durable Remission, Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab](http://www.ncbi.nlm.nih.gov/pubmed/24590637)Topalian SL, Sznol M, McDermott DF, JA, Hodi FS. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab Journal Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases](http://www.ncbi.nlm.nih.gov/pubmed/24563671)Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, Chen L, Kluger HM. PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases Journal HM. area as a predictor of sorafenib response in metastatic renal cell carcinoma Cancer Cell 14: 4. 24423208](https://pubmed.ncbi.nlm.nih.gov/24423208), and Survival in Metastatic Melanoma Following Radiosurgery](https://doi.org/10.1016/j.ijrobp.2013.06.717)Rutter C, Giesen E, Yu J, Bindra R, Kluger H, Chiang V. Influence of BRAF and NRAS Mutations on Distant Intracranial Recurrence and Survival in Metastatic Melanoma Following Radiosurgery International Journal Of inhibits metastasis of melanoma](http://www.ncbi.nlm.nih.gov/pubmed/24037523)Scortegagna M, Ruller C, Feng Y, Lazova Kluger Li JL, SK, Rickert R, Genetic inactivation pharmacological delays Glazer PM. Radiation sensitivity and sensitization in melanoma Pigment Cell KT, Lee SJ, Kluger HM. Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).](https://doi.org/10.1200/jco.2013.31.18_suppl.cra9006)Sznol M, Kluger H, Hodi F, McDermott Carvajal R, Lawrence D, Topalian S, Atkins M, Powderly J, Sharfman W, Puzanov I, Smith D, Wigginton J, Kollia G, Gupta A, Sosman J. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza M. Nivolumab plus Ipilimumab in Advanced Melanoma New ONO-4538) in combination with ipilimumab in advanced melanoma (MEL).](https://doi.org/10.1200/jco.2013.31.15_suppl.9012)Wolchok J, Kluger H, Callahan M, Postow M, Gordon R, Segal N, Rizvi N, Lesokhin A, Reed K, Burke M, Caldwell A, Kronenberg S, Agunwamba B, Feely W, Hong Q, Horak C, Korman A, Wigginton J, Gupta A, Sznol M. Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). Journal Of Clinical Oncology 2013, 31: 9012-9012. [DOI: nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.](https://doi.org/10.1200/jco.2013.31.15_suppl.4514)Drake C, McDermott D, Sznol M, Choueiri T, Kluger H, Powderly J, Smith D, Sankar V, Gutierrez A, Wigginton J, Kollia G, Gupta A, Atkins M. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up. Oncology of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).](https://doi.org/10.1200/jco.2013.31.15_suppl.9010)Hamid O, Sosman J, Lawrence D, Sullivan R, Ibrahim N, Kluger H, Boasberg P, Flaherty K, Hwu P, Ballinger M, Mokatrin A, Kowanetz M, Chen D, Hodi F. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). Journal Of a phase II randomized discontinuation trial (RDT).](https://doi.org/10.1200/jco.2013.31.15_suppl.9094)Daud A, Kluger H, Edelman G, Gordon M, Schimmoller F, Weitzman A, Samuel T, Moussa A, Flaherty K, Shapiro G. Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT). Journal Of Clinical Oncology 2013, 31: 9094-9094. [DOI: 10.1200/jco.2013.31.15_suppl.9094](https://doi.org/10.1200/jco.2013.31.15_suppl.9094). [Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).](https://doi.org/10.1200/jco.2013.31.15_suppl.cra9006)Sznol M, Kluger H, Hodi F, McDermott Carvajal R, Lawrence D, Topalian S, Atkins M, Powderly J, Sharfman W, Puzanov I, Smith D, Wigginton J, Kollia G, Gupta A, Sosman J. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; Yushak M, Kluger in 2013, F, Kluger Y, Camp RL, Kluger HM. Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors BMC Clinical Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Annals Of Oncology : Official Journal Of The European Society For Medical / ESMO 2013, Camp RL, Kluger HM. Vascularity of primary and metastatic renal cell carcinoma specimens Journal Of Translational Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma Annals Of S, Narayan D, Bacchiocchi A, Cheng E, Xu F, Li P, Kluger H, Halaban R, Kluger Y. Integrated analysis of tumor samples sheds light on tumor heterogeneity. The Yale Journal Of Biology And Medicine 2012, HM. Drug targets and predictive biomarkers in the management of metastatic melanoma Pharmacogenomics And BH, Evans P, Bacchiocchi A, McCusker J, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan A, Holman EC, M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Melanoma: Lessons Learned ipilimumab era and the possibility of longer survival.](http://www.ncbi.nlm.nih.gov/pubmed/22702482)Knisely JP, Yu JB, Flanigan J, Sznol melanoma brain metastases in the ipilimumab era and the possibility of longer survival. Journal a phase II randomized discontinuation trial (RDT).](https://doi.org/10.1200/jco.2012.30.15_suppl.7514)Hellerstedt B, Edelman G, Vogelzang N, Kluger H, Yasenchak C, Shen X, Ramies D, Gordon M, Lara P. Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT). Journal Of Clinical phase II randomized discontinuation trial (RDT).](https://doi.org/10.1200/jco.2012.30.15_suppl.8531)Gordon M, Kluger H, Shapiro G, Kurzrock R, Edelman G, Samuel T, Moussa A, Ramies D, Laird A, Schimmoller F, Shen X, Daud A. Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT). Journal Of Clinical Oncology 2012, 30: 8531-8531. [DOI: 10.1200/jco.2012.30.15_suppl.8531](https://doi.org/10.1200/jco.2012.30.15_suppl.8531). - Wilson D'Andrea K, Rimm D, Kirkwood J, Kluger H, Lee S, Flaherty K, Nathanson K. Abstract 5557: Mutation analysis of melanoma tumor samples from ECOG 2603 clinical trial Kluger HM, Camp RL. CD70 expression patterns in renal cell Cells](http://www.ncbi.nlm.nih.gov/pubmed/22355357)Zito Camp R, Kluger HM, Chao HH. Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer the Nucleus while Blocking Its Apoptotic Function at Mitochondria](http://www.ncbi.nlm.nih.gov/pubmed/22304920)Lau E, Kluger H, Varsano T, ZA. PKC Promotes Oncogenic Functions of ATF2 in the Nucleus while Blocking Its Apoptotic Function Kluger HM. Chapter One Vertical Pathway Targeting in Cancer Therapy 2012, 65: 1-26. [PMID: 22959021](https://pubmed.ncbi.nlm.nih.gov/22959021), [DOI: 10.1016/b978-0-12-397927-8.00001-4](https://doi.org/10.1016/b978-0-12-397927-8.00001-4). Heller KN, Hoos A, Sznol M. Case Report: Response to Ipilimumab in a Patient With HIV With Metastatic Melanoma Flanigan J, Sznol M, Yu J. Outcomes of Melanoma Brain Metastasis Management with Gamma Knife Radiosurgery +/- Ipilimumab International Journal target of rapamycin (mTOR) in renal cell cancer](http://www.ncbi.nlm.nih.gov/pubmed/21834980)Elfiky AA, Aziz SA, Conrad PJ, Siddiqui S, Hackl W, Maira M, Robert CL, Kluger HM. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer Journal Of VL, Kluger HM. Melanoma Brain Metastases: Is It Time to Reassess the Bias? Current Problems Ubiquitin-binding Domains*](http://www.ncbi.nlm.nih.gov/pubmed/21659512)Scortegagna M, Subtil T, Qi J, Kim H, W, Gu W, Kluger H, Ronai ZA. USP13 Y, Sznol M, Ariyan S, Molinaro A, Halaban R. Plasma Markers for Identifying Patients with Metastatic Melanoma RL, Rimm DL, Dudek A, Sznol M, Kluger HM. In vitro studies of dasatinib, its targets and predictors of sensitivity Pigment Cell Conrad P, Aziz S, Camp R, Schwartz B, Chen C, Kelly W, Kluger H. C-met as a therapeutic target using ARQ 197 in renal cell carcinoma. Journal Of Clinical Oncology 2011, 29: 360-360. [DOI: 10.1200/jco.2011.29.7_suppl.360](https://doi.org/10.1200/jco.2011.29.7_suppl.360). W, Kluger J, Lau E, Kallenberg DM, Jeong H, Eroshkin A, Bennett DC, Chin L, Bosenberg M, Jones N, Ronai ZA. A Role for ATF2 in Regulating RL, Rimm DL, Conrad P, Kluger HM. Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma LB, A, Sznol M. A phase 2 trial G, Jerusalem G, Gordon M, Kluger H, Moussa A, Ron I, Schimmoller F, Shen X, Daud A. 398 Phase 2 results of XL184 in a cohort of patients (pts) with advanced melanoma European Journal Of Cancer Supplements 2010, 8: [Benefits of Y, Camp Y. Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032](http://www.ncbi.nlm.nih.gov/pubmed/20630094)Rubinstein JC, Sznol M, Pavlick Bacchiocchi A, Kluger HM, Narayan D, Halaban R. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032 Journal Y, Kluger H, Stern DF. Centrosomal Chk2 in DNA damage responses and cell in with advanced melanoma.](https://doi.org/10.1200/jco.2010.28.15_suppl.8525)Hamid O, Sznol M, Pavlick A, Kluger H, Kim K, Boasberg P, Simantov R, Davis T, Crowley E, Hwu P. Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with 2010, Bepler G, Camp R, Kluger H. Abstract 1787: Dual targeting of PI3K and mTOR results in synergistic growth inhibition JM, Aziz S, Camp RL, Rimm DL, HM. DL. Melanoma Prognostic Model Using Tissue Microarrays and Genetic and biologic therapies for melanoma: do M, Camp RL, Rimm DL, Kluger HM. C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas Clinical and therapeutic target in breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/19717535)Nadler Y, Gonz\u00e1lez AM, Camp RL, Rimm factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer Annals of prognosis in breast cancer](https://doi.org/10.1200/jco.2009.27.15_suppl.11013)Giltnane J, Rapp J, Moeder C, Camp R, Kluger H, Molinaro A, Rimm D. Construction of a five-marker protein-based model for stage-independent assessment of prognosis in breast cancer Journal Of Clinical Oncology 2009, 27: 11013-11013. [DOI: 10.1200/jco.2009.27.15_suppl.11013](https://doi.org/10.1200/jco.2009.27.15_suppl.11013). [A phase I study of sunitinib combination with sirolimus in adults with advanced refractory malignancies](https://doi.org/10.1200/jco.2009.27.15_suppl.3554)Li J, Kluger H, Saif M, Murren J, Lee J, Kelly W, Rink L, Devine L, Sznol M. A phase I study of sunitinib in combination with sirolimus in adults with advanced refractory Journal Kluger Ritacco J, Adrada C, Phouyaphone N, Southard N, Sznol M. A phase II trial of dasatinib in advanced melanoma Journal Of glycoprotein (GPNMB) advanced melanoma](https://doi.org/10.1200/jco.2009.27.15_suppl.9032)Hwu P, Sznol M, Pavlick A, Kluger H, Kim K, Boasberg P, Sanders D, Simantov R, Crowley E, Hamid O. A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) (ADC), in a phase (Ph) I study of patients (pts) with advanced melanoma](https://doi.org/10.1200/jco.2009.27.15_suppl.9063)Sznol M, Hamid O, Hwu P, Kluger H, Hawthorne T, Crowley E, Simantov A. Pharmacokinetics (PK) of CR011-vcMMAE, an antibody-drug conjugate (ADC), in a phase (Ph) I study of patients (pts) with advanced melanoma Journal Of Clinical Oncology 2009, 27: 9063-9063. [DOI: 10.1200/jco.2009.27.15_suppl.9063](https://doi.org/10.1200/jco.2009.27.15_suppl.9063). - Aziz SA, Davies Pick Zito C, Jilaveanu L, Camp RL, Rimm DL, Kluger Y, Kluger HM. Phosphatidylinositol-3-Kinase as a Therapeutic Target in Sorafenib in Melanoma Patients Treated with Carboplatin, Paclitaxel by HuR in breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/19151756)Woo HH, Zhou Y, Yi X, David CL, Zheng W, Gilmore-Hebert M, Kluger HM, Ulukus EC, Baker T, Stoffer JB, Chambers SK. Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in Oncogene 2009, 1176-1186. [PMID: 19151756](https://pubmed.ncbi.nlm.nih.gov/19151756), [DOI: 10.1038/onc.2008.469](https://doi.org/10.1038/onc.2008.469). - Borden EC, Kluger H, Crowley J. Apoptosis: a clinical perspective Nature Reviews Drug Discovery 2008, 7: [PMID: 19065702](https://pubmed.ncbi.nlm.nih.gov/19065702), Rimm DL, Kluger HM, Kluger Y. Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer Clinical Cancer Research based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells](http://www.ncbi.nlm.nih.gov/pubmed/18626467)Kluger HM, Siddiqui SF, Angeletti C, Sznol M, Kelly WK, Molinaro AM, Camp RL. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial 2008, 88: 962-972. [PMID: 18626467](https://pubmed.ncbi.nlm.nih.gov/18626467), Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer](http://www.ncbi.nlm.nih.gov/pubmed/18528297)Acquavella N, Kluger J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M. Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell benign melanocytic lesions](http://www.ncbi.nlm.nih.gov/pubmed/18552823)Rothberg BE, Moeder CB, Kluger H, Halaban R, GF, Lazar A, Prieto V, Duncan LM, Rimm DL. non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer Kluger HM, Davis S, Subtil A, Meltzer P, Krajewski S, Jones N, Ronai Z. Suppressor role of activating transcription factor 2 (ATF2) in skin cancer Proceedings Of The National Academy Of Sciences Of The United States Of America 2008, 105: 1674-1679. [PMID: 18227516](https://pubmed.ncbi.nlm.nih.gov/18227516), MM, Kluger HM. Assessing Expression of Apoptotic Markers Using Large Microarrays 2008, 414: 83-93. 18175814](https://pubmed.ncbi.nlm.nih.gov/18175814), [DOI: 10.1007/978-1-59745-339-4_8](https://doi.org/10.1007/978-1-59745-339-4_8). - McCarthy M, Kluger H. Assessing Expression of Apoptotic Markers Using Large Cohort Tissue Microarrays 2008, 83-93. [DOI: 10.1007/978-1-59745-339-4_8](https://doi.org/10.1007/978-1-59745-339-4_8). - Pick E, McCarthy M, Kluger H. Assessing Expression of Apoptotic Markers Using Large Cohort Tissue Microarrays 2007, 414: 83-94. [DOI: 10.1385/1-59745-339-0:83](https://doi.org/10.1385/1-59745-339-0:83). - McCarthy MM, Lazova R, Camp RL, Rimm DL, Kluger HM. HSP90 as a marker of Decreased Survival in Cancer](http://www.ncbi.nlm.nih.gov/pubmed/17804730)Bromberg KD, Kluger HM, Delaunay A, Abbas S, DiVito KA, Z. Increased Expression of the E3 Ubiquitin Ligase RNF5 Is Associated with Decreased Survival in (RCC) based on the expression of VEGF and its receptors on tumor cells and microvessels: Identification of subsets with distinct patterns of expression, microvessel density, and outcome](https://doi.org/10.1200/jco.2007.25.18_suppl.15503)Camp R, Siddiqui S, Kelly W, Uchio E, Kluger H. Classification of renal cell carcinoma (RCC) based on the expression of VEGF and its receptors on tumor cells and microvessels: Identification of subsets with distinct patterns of expression, microvessel density, and outcome Journal Of Clinical Oncology 2007, 25: 15503-15503. [DOI: 10.1200/jco.2007.25.18_suppl.15503](https://doi.org/10.1200/jco.2007.25.18_suppl.15503). - Mehnert J, McCarthy M, Aziz S, Sznol M, Flaherty K, Camp R, Rimm D, Kluger H. VEGF, VEGFR1, and VEGFR2 25: 8520-8520. [DOI: 10.1200/jco.2007.25.18_suppl.8520](https://doi.org/10.1200/jco.2007.25.18_suppl.8520). - Aziz S, Pick-Golan E, McCarthy M, Flaherty K, Camp R, Rimm D, Kluger H. Assessment of PI3 kinase as a druggable target 2007, RL, Rimm DL, Kluger HM. High HSP90 Expression Is Associated with Decreased Survival in Breast Cancer Cancer Research HM, Alvero AB, Sznol M, Ariyan Camp RL, Rimm with R. Rab33A: Characterization, Expression, and Suppression by Epigenetic Modification Divito K, Camp R, Rimm D, Mor G. XIAP is highly expressed in melanoma and is associated with chemotherapy resistance Journal Of Clinical Oncology 2006, 24: 8008-8008. [DOI: 10.1200/jco.2006.24.18_suppl.8008](https://doi.org/10.1200/jco.2006.24.18_suppl.8008). Halaban R, Berger KT, Camp RL, Lazova R, Rimm DL, Kluger HM. Expression of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptors 1 and 2 in from JR, Kluger HM. Metastatic myoepithelial carcinoma of the vulva Tuck D. Association between pathways in regulatory networks Annual International Conference Of The IEEE Engineering In Medicine And Biology Society (EMBC) 2006, Camp RL, Rimm DL, Kluger HM. Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer 16033835](https://pubmed.ncbi.nlm.nih.gov/16033835), [DOI: Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive Disease](http://www.ncbi.nlm.nih.gov/pubmed/15994930)Kluger HM, Lev D, Kluger Y, McCarthy MM, Kiriakova G, Camp RL, Rimm DL, Price JE. Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive Disease Cancer Research 2005, 65: 5578-5587. [PMID: 15994930](https://pubmed.ncbi.nlm.nih.gov/15994930), [DOI: 10.1158/0008-5472.can-05-0108](https://doi.org/10.1158/0008-5472.can-05-0108). Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/15930343)Harigopal M, Berger AJ, Camp RL, Rimm DL, Kluger HM. Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer Clinical Cancer Research 2005, 11: 4083-4089. [PMID: 15930343](https://pubmed.ncbi.nlm.nih.gov/15930343), [DOI: 10.1158/1078-0432.ccr-04-2191](https://doi.org/10.1158/1078-0432.ccr-04-2191). Sznol M, Rimm D, Kluger H. Expression and prognostic value of TRAIL receptors R1 and R2 in early stage breast cancer Journal Of Clinical Oncology 2005, 23: 9528-9528. [DOI: 10.1200/jco.2005.23.16_suppl.9528](https://doi.org/10.1200/jco.2005.23.16_suppl.9528). [Automated Quantitative Analysis Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome](http://www.ncbi.nlm.nih.gov/pubmed/15574789)Berger AJ, Camp RL, DiVito KA, Kluger HM, Halaban R, Rimm DL. Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome 2004, 64: 8767-8772. 15574789](https://pubmed.ncbi.nlm.nih.gov/15574789), [DOI: 10.1158/0008-5472.can-04-1384](https://doi.org/10.1158/0008-5472.can-04-1384). [Automated Quantitative Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma](http://www.ncbi.nlm.nih.gov/pubmed/15574790)Divito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM. Automated Quantitative Analysis of Tissue Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma Cancer Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, Wu T, Niinobe M, Yoshikawa K, Hannigan GE, Halaban R. Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to K, Zhao H, Ariyan S, Lin A, Kluger H, Berger A, Cheng E, Trombetta E, Wu T, Halaban R, Niinobe M, Yoshikawa K, Hannigan G. Expression profiling reveals novel pathways in the transformation of Melanocytes to Melanomas. Pigment Cell Melanoma [DOI: 10.1111/j.1600-0749.2004.00175_12.x](https://doi.org/10.1111/j.1600-0749.2004.00175_12.x). - Divito M, Camp Berger A, Rimm D, Kluger H. Evaluation of Bcl-2 expression in melanoma - A tissue microarray study Journal Clinical 22: 7515-7515. [DOI: 10.1200/jco.2004.22.14_suppl.7515](https://doi.org/10.1200/jco.2004.22.14_suppl.7515). - Divito Camp Berger A, Rimm D, Kluger H. Evaluation of Bcl-2 expression in melanoma - A tissue microarray study Journal Clinical 22: 7515-7515. - CheloucheLev Berger AJ, Rimm DL, Price JE. Bcrystallin as a marker of lymph node involvement in breast carcinoma Cancer 2004, 100: 2543-2548. [PMID: 15197794](https://pubmed.ncbi.nlm.nih.gov/15197794), [DOI: 10.1002/cncr.20304](https://doi.org/10.1002/cncr.20304). [Her2/neu is not a commonly expressed therapeutic target in melanoma - a large cohort tissue microarray study](http://www.ncbi.nlm.nih.gov/pubmed/15179190)Kluger HM, DiVito K, Berger AJ, Halaban R, Ariyan S, Camp RL, Rimm DL. Her2/neu is not a commonly expressed therapeutic target in melanoma - a large cohort tissue microarray microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model Laboratory [PMID: 14767486](https://pubmed.ncbi.nlm.nih.gov/14767486), [DOI: 10.1038/labinvest.3700044](https://doi.org/10.1038/labinvest.3700044). Price J. Alpha B crystallin, a novel marker for breast cancer metastasis Annals Colony-Stimulating Factor-1 Receptor Expression Is Associated with Poor Outcome in Breast Cancer by Large Cohort Tissue Microarray Analysis](http://www.ncbi.nlm.nih.gov/pubmed/14734466)Kluger HM, Dolled-Filhart Colony-Stimulating Factor-1 Receptor Expression Is Associated with Poor Outcome in Breast Cancer by Large Cohort Tissue Microarray Analysis Clinical Cancer Research 2004, 10: 173-177. [PMID: 14734466](https://pubmed.ncbi.nlm.nih.gov/14734466), [DOI: 10.1158/1078-0432.ccr-0699-3](https://doi.org/10.1158/1078-0432.ccr-0699-3). [Subcellular localization of 2 in melanoma specimens predicts patient survival.](http://www.ncbi.nlm.nih.gov/pubmed/14678960)Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, Rimm DL. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Research 2003, 63: 8103-7. [PMID: 14678960](https://pubmed.ncbi.nlm.nih.gov/14678960). - Yale Cancer Center - Melanoma ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 8New Haven, CT 06511 - Yale Cancer Center - Melanoma ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, "}